Upload
others
View
3
Download
0
Embed Size (px)
Citation preview
ESSENTIAL MEDICINES LIST
October 2014
This publication was produced for review by the U.S. Agency for International Development. It was prepared by the USAID | DELIVER PROJECT, Task Order 4.
The authors’ views expressed in this publication do not necessarily reflect the views of the U.S. Agency for International Development or the United States Government.
ESSENTIAL MEDICINES LIST | 3
CONTENTS
Acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
Symbols and Terms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Foreword . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
Acknowledgment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Essential Medicines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Using the Essential Medicines List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
EML for BHUs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
EML for RHCs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
EML for THQs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
EML for DHQs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
Figures
1. Development of Essential Medicines List . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2. Percentage of Total Deaths for All Ages in Pakistan . . . . . . . . . . . . . . . . . . . . . . 17
3. Structure of Provincial Health System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Table
1. Medicines with Age or Weight Restrictions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Recommended Citation The Department of Health, Government of Balochistan, Pakistan. 2014. Essential Medicines List. Islamabad, Pakistan: USAID | DELIVER PROJECT, Task Order 4, for the Department of Health, Government of Balochistan, Pakistan.
Abstract The Department of Health, Government of Balochistan, formally approached the USAID | DELIVER PROJECT in 2012, seeking technical support to develop EMLs for the primary- and secondary-level health facilities in the province. The project quickly mobilized its resources to respond to this request; they developed customized EMLs after detailed consultation with all stakeholders, including health and medical professionals from the WHO (Pakistan office), as well as the districts. The Department of Health, Government of Balochistan, is pleased to announce the first-ever province-specific EMLs for primary- and secondary-level health facilities; they meet WHO standards and WHO Pakistan has endorsed them.
USAID | DELIVER PROJECT/IslamabadHouse No 253 C Street 23 Sector E 7 Islamabad, Pakistan Phone: 92.051.2655425 Fax: 92.051.2655427 Email: [email protected] Internet: deliver.jsi.com
ESSENTIAL MEDICINES LIST | 5
ACRONYMS
BOD burden of disease
CDC Centers for Disease Control and Prevention
DOH Department of Health
DRAP Drug Regulatory Authority of Pakistan
EDL Essential Drugs List
EML Essential Medicines List
ENT ear, nose, throat
EPI Expanded Programme on Immunization
GIT gastrointestinal
HCl hydrochloride
HSRU Health Sector Reform Unit
IDU injecting drug user
INN international non-proprietary names
IU international unit
MDR multidrug-resistance
MIU million international units
MOH Ministry of Health
ESSENTIAL MEDICINES LIST | 7 6 | ESSENTIAL MEDICINES LIST
MSW male sex worker
NCD non-communicable disease
NEML National Essential Medicines List
PIH pregnancy induced hypertension
PVRV purified vero cell rabies vaccine
BPPR Balochistan Public Procurement Rules
UNICEF United Nations Children’s Fund
USAID U.S. Agency for International Development
WHO World Health Organization
w/v weight by volume
SYMBOLS AND TERMS
Note: The drugs listed in this medicines list are generic drugs; therefore, the names of the medicines are always written in lowercase letters.
The following symbols are used throughout this list of medicines:
ª Primarily indicates similar clinical performance within a pharmacological class.
ò Indicates that the medicine has an age or weight restriction.
© Signifies a specific indication for restricting its use for children.
ACRONYMS
ESSENTIAL MEDICINES LIST | 9
FOREWORD
The right to health is a fundamental human right and provision of essential medicines is one of the essential components of primary health care. A standardized Essential Medicines List can meet end users’ requirements
and help rationalizing the purchase and distribution of medicines, thereby, reducing costs of the healthcare. .
The World Health Organization (WHO) defines Essential Medicines as “those that satisfy the priority health care needs of the population”. They are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality, and at a price the individual and the community can afford.
Before 2011, it was the responsibility of the Federal Ministry of Health to develop and update Essential Medicines Lists (EMLs) while provinces were maintaining medicines procurement lists based on their field requirements. However, after the 18th Constitutional Amendment in June 2011, when all administrative and financial powers were devolved to the provinces, it was acknowledged by the Department of Health, Government of Balochistan, that there should be segregated lists of essential medicines for each facility level.
The Department of Health, Government of Balochistan, formally approached USAID | DELIVER PROJECT in 2012, for seeking technical support to develop EMLs for the primary and secondary level health facilities in the province. The Project quickly mobilized its resources to respond this request and developed customized EMLs after detailed consultation with all stakeholders, including health and medical professionals from the WHO (Pakistan office) as well as districts. The Department of Health, Government of Balochistan, is pleased to announce the
ESSENTIAL MEDICINES LIST | 11 10 | ESSENTIAL MEDICINES LIST
first ever province-specific EMLs for primary and secondary level health facilities that meet WHO standards and have also been endorsed by WHO Pakistan. The EMLs have been distributed among all stakeholders up to districts level for implementation.
The Department of Health will convene a provincial committee in Balochistan with a proportionate representation of health and medical professionals. This committee will be reviewing and updating the EMLs regularly based on end users’ requirements and an updated version will be available at http://www.balochistan.gov.pk/health.
I would like to express my gratitude to USAID/Pakistan for providing the support through USAID | DELIVER PROJECT for development of province-specific standard EMLs for Balochistan. I am also grateful to the WHO/Pakistan for extending their technical support in the accomplishment of the EMLs. Their concurrent support will contribute to ensuring transparency and value for money in procurement, enhancing performance of health professionals, and ensuring availability of quality medicines for the people of Balochistan.
Secretary, Department of Health Government of Balochistan
ACKNOWLEDGMENT
The Essential Medicines Lists (EMLs) have been developed for primary and secondary level healthcare facilities of the Department of Health (DOH), Government of Balochistan, with the technical and financial
support of United State Agency for International Development (USAID)-funded USAID | DELIVER PROJECT, and with the technical guidance of the World Health Organization (WHO) Pakistan Office. Moreover, the health and medical professionals from district health offices and public sector health institutions of Balochistan have also contributed and provided valuable inputs in finalizing the EMLs.
I would like to express my deepest appreciation to all relevant public sector stakeholders, development partners, health specialists and medical professionals from WHO/Pakistan for reviewing, contributing, guiding and supporting the development of the EMLs for primary and secondary healthcare facilities of Balochistan.
The DOH highly appreciates the auspicious and productive support of USAID/Pakistan towards strengthening the health sector of the Balochistan province. I would like to thank Mr. Randolph Augustin, Director, Health Office, USAID | Pakistan and Mr. Khalid Saeed Bukhari of WHO Pakistan for their leadership and coordinated support enabling the USAID | DELIVER PROJECT to successfully produce the EMLs.
We also wish to appreciate Dr. Muhammad Tariq, Country Director, USAID | DELIVER PROJECT Pakistan for his leadership role and his dedicated team for their devoted efforts and support provided in developing the EMLs.
Director General Health Services, Department of Health Government of Balochistan
FOREWORD
ESSENTIAL MEDICINES LIST | 13
ESSENTIAL MEDICINES
Medicines have a major role in protecting, maintaining, and restoring health. Policymakers and departments implementing health activities and programs are responsible for providing appropriate quality
medicines, in adequate quantities, at reasonable prices.
However, to ensure equitable access to quality medicines and to promote their rational use, developing countries still face challenges—even though governments, development agencies, and the World Health Organization (WHO) continue their efforts. Recently, the reforms in health sector financing, globalization, and economic recessions have shown improved access to essential medicines.
The publication, WHO Model List of Essential Medicines (WHO 2011b), is a guide for developing national and institutional essential medicines lists. This model list is regularly revised.
Essential medicines are—
• intended to satisfy the priority healthcare needs of the population
• selected with regard to disease prevalence, evidence on efficacy and safety, and comparative cost effectiveness
• intended to be available within the context of functioning health systems, at all times; in adequate amounts, in appropriate dosage forms, with assured quality, and at a price the individual and the community can afford
ESSENTIAL MEDICINES LIST | 15 14 | ESSENTIAL MEDICINES LIST
• one of the most cost-effective elements in modern healthcare; their potential health impact is enormous.
The WHO list is regularly updated with a selection of medicines that reflect new therapeutic options and changing therapeutic needs. It helps to ensure drug quality and to continue developing better medicines—medicines for emerging diseases and medicines to meet changing resistance patterns.
WHAT ARE ESSENTIAL MEDICINES?Since 2002, essential medicines have been defined as “those that satisfy the priority health-care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility.” This definition evolved from the first definition in 1977 (WHO 1977), which was adopted in the Alma-Ata Declaration of 1978 (WHO 1978). The main change has been the selection process—from an experts-based approach to an evidence-based approach.
An EML includes a limited number of carefully selected medicines. These lists have been published as formularies and institutional lists of medicines, which are made available to health facilities and health workers. The list may not always be called an EML; but, whatever name is used, they all serve the same function. EMLs have been one cornerstone of public health delivery and the basis for efforts to ensure consistent medicine supply and management. It is an important strategy for improving access to and use of medicines, especially for the vulnerable segment of a population. Furthermore, an EML can be an advocacy tool to help countries spend their limited resources on the medicines that are most needed and that offer the best value for the money.
WHO recommends the following process to develop a national EML (see figure 1).
Figure 1 . Development of Essential Medicines List
PAKISTAN NATIONAL ESSENTIAL MEDICINES LISTTo address the disease burden in Pakistan, as noted above, the National Essential Medicines (Drugs) List (NEML) of Pakistan was first prepared in 1994, after consultations with experts in the field. The list was reviewed in 1995, 2000, 2003, and 2007. The former Federal Ministry of Health (MOH) previously published and disseminated this list to healthcare professionals as part of an
Disease Burden
Evidence-based Standard Treatment Guidlines (STGs)
By Level
(EML)
Essential Medicines List
ESSENTIAL MEDICINES ESSENTIAL MEDICINES
ESSENTIAL MEDICINES LIST | 17 16 | ESSENTIAL MEDICINES LIST
effort to increase the acceptability of the concept, as envisaged in the National Drug Policy. The former MOH expected the provincial health departments and the local health authorities to procure the drugs recommended on the list. Although the list was not followed exactly in practice, the concept remains the best cost-effective mechanism for the public procurement of drugs; therefore, using the EML should be encouraged.
Recently the Drug Regulatory Authority of Pakistan (DRAP), in collaboration with WHO Pakistan, has prepared and published the National EML 2014.
WHO discourages using the term Essential Drugs Lists (EDL) because the word Drugs is also commonly used for narcotics and other stimulant drugs. Therefore, WHO recommends using the title Essential Medicines List (EML).
PAKISTAN FACING A DOUBLE BURDEN OF DISEASEThe burden of disease (BOD) in Pakistan is dominated by communicable diseases, reproductive health problems, and malnutrition; which, collectively, account for about 50 percent of the total (WHO 2013). This includes a high maternal mortality ratio (276/100,000 live births); low antenatal care coverage (61 percent); frequent complications of pregnancy and child birth; low family planning coverage (30 percent); and a high ratio of children under 5 years, infant, and neonatal mortality (94, 78, and 54/1,000 live births, respectively). Malnutrition in the young is an underlying cause of more than 50 percent of the deaths—one-fifth of newborns have low birth weight and 38 percent of children under 5 years of age are underweight. These health issues are aggravated by a low exclusive breastfeeding rate for infants’ under 6 months (37 percent of children) and low vaccination coverage (47 percent). Added to this burden are non-communicable diseases (NCD), including cardiovascular disease, diabetes, cancer, injuries, and neuro-psychiatric disorders. This double BOD is a major challenge in the health sector of Pakistan. Respiratory infections and diarrheal diseases are still the major fatal diseases in Pakistan, particularly for children under 5. Pakistan is the second country (after India) in Southeast Asia that is moving toward a concentrated HIV and AIDS epidemic stage for groups like injecting drug users (IDUs) and male sex workers (MSWs). The percentage
mortality rates for Pakistan for 2008 estimates are represented in figure 2 (WHO 2011a).
Figure 2 . Percentage of Total Deaths for All Ages in Pakistan
ACTIVITIES AND PROCESS ADOPTED TO DEVELOP EMLSExtensive Internet research produced data and other available information, including websites for WHO, United Nations Children’s Fund (UNICEF), Centers for Disease Control and Prevention (CDC), Department of Health (DOH) Balochistan, Balochistan Health Sector Reform Unit (HSRU), and many other relevant resource organizations. To access information on available EMLs and procurement lists, consultative meetings were held with the WHO Pakistan
Communicable, Material, Perinatal, and Nutritional Conditions
46%
Respiratory Diseases 5%
Injuries 8%
CVD 25%
Cancers 7%
Diabetes 1%
Other NCDs 8%
ESSENTIAL MEDICINES ESSENTIAL MEDICINES
ESSENTIAL MEDICINES LIST | 19 18 | ESSENTIAL MEDICINES LIST
team, as well as the provincial- and district–health officials. All the material/information collected was reviewed; a completed situation analysis identified the gaps and challenges.
After completing these steps, recommended procurement lists for essential drugs/medicines were developed for each primary- and secondary-level healthcare facility for the Department of Health, Balochistan. These lists are based on the WHO Model List of Essential Medicines, WHO treatment guidelines and feedback, and observations from visits to health facilities. The draft lists were shared with WHO Pakistan; after several consultations, a final draft was endorsed by WHO, which was then shared with the provincial- and district–health officials of Balochistan in a consultative workshop (see figure 3). The recommendations from the workshop were incorporated and the Balochistan Health Department approved the lists for implementation across the province.
Figure 3 . Structure of Provincial Health System
Referrals Referrals
Provincial Department
of Health
DHOs District Health
Officers
Civil Surgeons DHQ Hospitals
Tertiary Hospitals
BHUs RHUsTHQ
Hospitals
R e f e r r a l s
USING THE ESSENTIAL MEDICINES LIST
Use the EML for standardized procurement. The EML uses the international non-proprietary names (INN) classification, which is the official shortened scientific name or generic name of the medicine,
based on the active ingredient. Using the INN reduces the risk of duplication, confusion, or errors in identifying a product. For example, cotrimoxazole—the official or generic name—is easier to recognize and remember than the range of alternatives, such as Septran, Bactrim, etc.; and it avoids mistakes in prescribing, dispensing, and ordering. Generic drugs/medicines are also usually much cheaper than proprietary drugs. Rule 13 of Balochistan Public Procurement Rules (BPPR) 2013 also prohibits the use of proprietary or brand names.
EMLs help simplify the quantification of drug requirements and the training for those prescribing and dispensing drugs. If only a limited number of drugs are used, health workers will be more familiar with indications, dosages, side effects, and contraindications.
ESSENTIAL MEDICINES
ESSENTIAL MEDICINES LIST | 21 20 | ESSENTIAL MEDICINES LIST
EXPLANATORY NOTES
The segregated core lists presents the list of minimum medicine needs for a basic healthcare system; it lists the most efficacious, safe, and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance and the potential for safe and cost-effective treatment.
ª The square box ª symbol primarily indicates similar clinical performance within a pharmacological class . The listed medicines are examples of the class with the best evidence for effectiveness and safety . In some cases, this may be the first medicine licensed for marketing; in other cases, subsequently licensed compounds may be safer or more effective . If the efficacy and safety data are the same, the listed medicine is the one that is generally available at the lowest price, based on international drug price information sources . Not all square boxes are applicable to medicine selection for children . Therapeutic equivalence is only indicated based on the reviews of efficacy and safety and when consistent with WHO clinical guidelines .
ò The ò symbol indicates an age or weight restriction for the medicine; see table 1 for details for each medicine .
© The © symbol signifies a specific indication for restricting its use for children .
An entry on the EML carries no assurance of pharmaceutical quality. It is the responsibility of the relevant procurement authority to ensure that each product is of appropriate pharmaceutical quality (including stability); and that, when relevant, different products are interchangeable.
Medicines and dosage forms are listed in alphabetical order within each section; one form is not preferred over another. Consult standard treatment guidelines for information on appropriate dosage forms.
Table 1 . Medicines with Age or Weight Restrictions
atazanavir >25 kg
atropine >3 months
benzyl benzoate >2 years
betamethasone topical preparations hydrocortisone preferred for neonates
cefazolin >1 month
ceftriaxone >41 weeks corrected gestational age
chlorphenamine >1 year
diloxanide >25 kg
doxycycline >8 years (except for serious infections, e .g ., cholera)
efavirenz >3 years or >10 kg
emtricitabine >3 months
fluoxetine >8 years
ibuprofen >3 months (except IV form for patent ductus arteriosus)
mefloquine >5 kg or >3 months
metoclopramide not for neonates
ondansetron >1 month
saquinavir >25 kg
silver sulfadiazine >2 months
tetracaine not for preterm neonates
trimethoprim >6 months
xylometazoline >3 months
USING THE ESSENTIAL MEDICINES LISTUSING THE ESSENTIAL MEDICINES LIST
ESSENTIAL MEDICINES LIST | 23
REFERENCES
World Health Organization (WHO). 1978. Declaration of Alma-Ata International Conference on Primary Health Care, Alma-Ata, USSR, 6-12 September 1978. Geneva: WHO. Available at http://www.who.int/publications/almaata_declaration_en.pdf?ua=1 (accessed October 21, 2014)
World Health Organization (WHO). 2002. Promoting Rational Use of Medicines: Core Components - WHO Policy Perspectives on Medicines, No. 005, September 2002. Available from: http://apps.who.int/medicinedocs/en/d/Jh3011e/2.html (accessed October 21, 2014)
World Health Organization (WHO). 2011a. NCD Country Profiles. Geneva: WHO. Available at http://www.who.int/nmh/countries/pak_en.pdf (accessed October 21, 2014)
World Health Organization (WHO). 2011b. WHO Model List of Essential Medicines. Geneva: WHO.
World Health Organization (WHO). 2013. Pakistan: Country Cooperation Strategy at a glance. Geneva: WHO. Available at http://www.who.int/countryfocus (accessed October 21, 2014)
ESSENTIAL MEDICINES LIST | 25
EML FOR BHUs
ª Primarily indicates similar clinical performance within a pharmacological class.
ò Indicates that the medicine has an age or weight restriction.
© Signifies a specific indication for restricting its use for children.
ESSENTIAL MEDICINES LIST | 27
EML FOR BHUs
BH
Us
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
A
Ane
sthe
tics
loca
l 1
lidoc
aine
(hy
droc
hlor
ide)ª
vial
/am
poul
e2%
w/v
(10
ml)
topi
cal
2% g
el (
15gm
)
B
Ana
lges
ics/
NSA
IDs
2ac
etyl
salic
ylic
aci
d (d
ispe
rsib
le/
solu
ble)
tabl
et10
0mg
to 5
00m
g
3ac
etyl
salic
ylic
aci
dsu
ppos
itory
50m
g to
150
mg
4di
clof
enac
(so
dium
)am
pule
75m
g in
3m
l
5ib
upro
fenò
tabl
et20
0mg,
400m
g
syru
p20
0mg/
5ml
6pa
race
tam
ol
tabl
et50
0mg
syru
p12
5mg/
5ml
supp
osito
ry10
0mg
C
Ant
i-Alle
rgic
s an
d m
edic
ines
use
d in
an
aphy
laxi
s7
chlo
rphe
nira
min
e
(hyd
roge
n m
alea
te)ò
ª
tabl
et4m
g
syru
p©2 .
5mg/
5ml
inje
ctio
n10
mg/
ml
8de
xam
etha
sone
(di
sodi
um
phos
phat
e)in
ject
ion
4mg/
ml
9ep
inep
hrin
e (a
dren
alin
e)am
pule
1mg/
ml
10hy
droc
ortis
one
(sod
ium
su
ccin
ate)
inje
ctio
n10
0mg,
250m
g
11pr
edni
solo
neª
tabl
et5m
g
12lo
ratid
ine
tabl
et10
mg
syru
p1m
g/m
l
ESSENTIAL MEDICINES LIST | 29 28 | ESSENTIAL MEDICINES LIST
EML FOR BHUsEML FOR BHUs
BH
Us
BH
Us
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
A
NT
I-IN
FEC
TIV
ES
D
Ant
ibio
tics/
an
timic
robi
als
13
amox
icill
in (
trih
ydra
te)
caps
ule/
tab
let
250m
g, 50
0mg
(pre
fera
bly
disp
ersi
ble
tabl
et)
syru
p©12
5mg,
250m
g/5m
l
inje
ctio
n25
0mg,
500m
g
14am
pici
llin
(as
sodi
um s
alt)
in
ject
ion
500m
g an
d 1g
15ci
profl
oxac
in (h
ydro
chlo
ride
)ªta
blet
250m
g, 50
0mg
16co
trim
oxaz
oleò
tabl
et©
400m
g +
80m
g
(sul
fam
etho
xazo
le +
tr
imet
hopr
im)
syru
p©20
0mg
+ 4
0mg/
5ml
17ª
met
roni
dazo
le
(ben
zoat
e)
tabl
et20
0mg,
400m
g
syru
p20
0mg/
5ml
E
Ant
i-Hel
min
thic
18m
eben
dazo
le (
chew
able
)ta
blet
500m
g
(with
cau
tion,
onl
y fo
r ad
ults
)
syru
p10
0mg/
5ml
F
Ant
i-Fun
gal
19ny
stat
in
tabl
et50
0,00
0 IU
drop
s©10
0,00
0 IU
/ml
pess
ary
100
000
IU
20cl
otri
maz
ole
vagi
nal c
ream
1%
vagi
nal t
able
t10
0mg
and
500m
g
G
Ant
i-Tub
ercu
losi
s m
edic
ines
21et
ham
buto
lta
blet
400m
g
oral
liqu
id©
25m
g/m
l
As p
er T
B co
ntro
l pro
gram
gu
idel
ines
22is
onia
zid
tabl
et/s
yrup
©50
mg,
100m
g, 30
0mg
23py
razi
nam
ide
tabl
et50
0mg
24ri
fam
pici
nca
psul
e/sy
rup©
150m
g, 30
0mg,
450m
g, 60
0mg
25st
rept
omyc
inin
ject
ion
1gm
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
26et
ham
buto
l + is
onia
zid
tabl
et40
0mg
+ 1
50m
g
27is
onia
zid
+ r
ifam
pici
nta
blet
75m
g +
150
mg;
150m
g +
300
mg
28is
onia
zid
+ p
yraz
inam
ide
+
rifa
mpi
cin
tabl
et75
mg
+ 4
00m
g +
150
mg
29ri
fam
pici
n +
ison
iazi
d +
py
razi
nam
ide
+ e
tham
buto
lta
blet
150m
g +
75m
g +
40
0mg
+ 2
75m
g
30et
ham
buto
l + is
onia
zid
+
rifa
mpi
cin
tabl
et27
5mg
+ 7
5mg
+ 1
50m
g
H
Ant
imal
aria
l31
chlo
roqu
ine
(pho
spha
te o
r su
lfate
)ta
blet
150m
g
For
vivax
32pr
imaq
uine
(di
phos
phat
e)ta
blet
15m
g
For
falci
paru
m
33
arte
suna
te +
sul
phad
oxin
e an
d py
rim
etha
min
eta
blet
co-b
liste
r of
(6
+ 2
) ta
blet
—tw
o la
rge
tabl
ets,
each
has
sul
fado
xine
50
0mg
U .S
.P . +
pyr
imet
ham
ine
25m
g U
.S .P
—an
d si
x sm
all t
able
t, ea
ch
cont
ains
art
esun
ate
50m
g U
.S .P .
To b
e us
ed in
com
bina
tion
(co-
blist
er)
arte
suna
te +
sul
phad
oxin
e an
d py
rim
etha
min
eta
blet
co-b
liste
r of
(6
+ 3
) ta
blet
—th
ree
larg
e ta
blet
s, ea
ch h
as s
ulfa
doxi
ne
500m
g U
.S .P .
+ p
yrim
etha
min
e 25
mg
U .S
.P .—
six
smal
l tab
let,
each
co
ntai
ns a
rtes
unat
e 10
0mg
U .S
.P .
34ar
tesu
nate
tabl
et50
mg
I A
nti-D
iabe
tics
35gl
iben
clam
ide
tabl
et5m
g
36m
etfo
rmin
(hy
droc
hlor
ide)
tabl
et50
0mg
37in
sulin
reg
ular
inje
ctio
n10
0 IU
/ml
38in
sulin
com
pin
ject
ion
30%
+ 7
0% w
/v
ESSENTIAL MEDICINES LIST | 31 30 | ESSENTIAL MEDICINES LIST
EML FOR BHUsEML FOR BHUs
BH
Us
BH
Us
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
J C
ardi
ovas
cula
r m
edic
ines
39fu
rose
mid
eªta
blet
20m
g, 40
mg
inje
ctio
n10
mg
40gl
ycer
yl t
rini
trat
esu
blin
gual
500m
cg
41m
ethy
ldop
ata
blet
250m
g
42en
alap
ril (
mal
eate
)ta
blet
5mg,
10m
g
K
Gas
troi
ntes
tinal
(G
IT)
med
icin
es43
hyos
cine
(bu
tylb
rom
ide)
inje
ctio
n20
mg/
ml
tabl
ets
10m
g
44ph
loro
gluc
inol
tabl
ets
phlo
rogl
ucin
ol 8
0mg
+
trim
ethy
lphl
orog
luci
nol 8
0mg
45m
etoc
lopr
amid
e
(hyd
roch
lori
de)ò
tabl
ets
10m
g
syru
p5m
g/5m
l
inje
ctio
n5m
g/m
l
46om
epra
zoleª
caps
ules
10m
g, 20
mg,
40m
g
47ra
nitid
ine
inje
ctio
n25
mg/
ml i
n 2m
l
48al
umin
ium
hyd
roxi
de +
m
agne
sium
tri
silic
ate
tabl
ets
250m
g +
500
mg
Reco
mm
ende
d in
co
mbi
natio
n w
ith z
inc
sulp
hate
20m
g di
sper
sible
ta
blet
for
acut
e di
arrh
ea49
OR
S (lo
w o
smol
arity
)Sa
chet
dry
mix
ture
(lo
w o
smol
arity
fo
rmul
a) in
sac
het
for
1 lit
er o
f so
lutio
n, e
ach
sach
et c
onta
ins
gluc
ose
anhy
drou
s 13
.5gm
B .P .
, tr
isod
ium
citr
ate
dihy
drat
e 2 .
9gm
B .
P . po
tass
ium
chl
orid
e1 .5
gm B
.P .,
sodi
um c
hlor
ide
2 .6g
m B
.P .
50
glyc
erin
supp
osito
ry
LR
espi
rato
ry m
edic
ines
51sa
lbut
amol
(su
lfate
)ªta
blet
2 an
d 4m
g
solu
tion
5mg/
ml f
or n
ebul
izer
52am
inop
hylli
nein
ject
ion
25m
g/m
l
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
M
Mis
cella
neou
s53
atro
pine
(su
lfate
)òam
pule
1mg
in 1
ml
54ch
arco
al a
ctiv
ated
pow
der
55di
azep
amin
ject
ion
10m
g
gel o
r re
ctal
sol
utio
ns5m
g/m
l in
0 .5m
l; 2m
l; 4-
ml
For
ecle
mps
ia o
nly
56m
agne
sium
sul
phat
ein
ject
ion
500m
g/m
l
57na
loxo
ne (
hydr
ochl
orid
e)in
ject
ion
400m
cg in
1m
l
58ox
ygen
con
cent
rato
r/cy
linde
r
N
Oph
thal
mic
/EN
T59
boro
glyc
erin
eea
r dr
ops
(o
nly
for
wax
rem
ovin
g)40
.00%
60po
lym
yxin
B s
ulph
ate
+
ligno
cain
eea
r dr
ops
each
ml c
onta
ins
poly
myx
in
B (s
ulph
ate)
:100
0IU
/m
l,Lig
noca
ine:
50m
g/m
l]; 5
ml p
last
ic
bott
le
61ch
lora
mph
enic
ol
eye
drop
s1%
w/v
, 0 .5
% w
/v
62ge
ntam
icin
(su
lfate
)ey
e dr
ops
0 .30
%
63po
lym
yxin
B (
sulp
hate
) +
ba
citr
acin
zin
cey
e oi
ntm
ent
10,0
00 IU
/g +
500
IU/g
O
I/V in
fusi
ons
64de
xtro
se +
sal
ine
infu
sion
5% +
0 .9
% w
/v
Plas
ma
subs
titut
es65
gluc
ose/
dext
rose
infu
sion
5%,1
0%
66no
rmal
sal
ine
infu
sion
0 .9%
67R
inge
r la
ctat
ein
fusi
on
infu
sion
1,00
0ml c
onta
ins
calc
ium
ch
lori
de 0
.2gm
U .S
.P .; p
otas
sium
ch
lori
de 0
.3gm
U .S
.P .; s
odiu
m
chlo
ride
6gm
U .S
.P .; 3
.1gm
sod
ium
la
ctat
e U
.S .P .
, ste
rile
wat
er fo
r in
ject
ion
1,00
0ml (
q .s .
),1,0
00m
l co
llaps
ible
pla
stic
bot
tle
68w
ater
for
inje
ctio
nam
pule
5ml a
nd 1
0ml
ESSENTIAL MEDICINES LIST | 33 32 | ESSENTIAL MEDICINES LIST
EML FOR BHUsEML FOR BHUs
BH
Us
BH
Us
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
PV
itam
ins
and
min
eral
s69
asco
rbic
aci
dta
blet
50m
g, 10
0mg,
500m
g
Mic
ronu
trie
nts
70ca
lciu
m g
luco
nate
inje
ctio
n10
0mg/
ml i
n 10
ml
71ca
lciu
m la
ctat
eta
blet
500m
g, 1g
m
72er
goca
lcife
rol (
vita
min
D)ª
tabl
et1 .
25m
g (5
0,00
0 IU
)
73fe
rrou
s sa
lt (fu
mer
ate)
tabl
eteq
uiva
lent
to
60m
g ir
on
syru
peq
uiva
lent
to
25m
g/m
l iro
n
74fo
lic a
cid
tabl
et0 .
5mg,
1mg,
and
5mg
75fe
rrou
s sa
lt +
folic
aci
dta
blet
(D
RA
P ap
prov
ed)
tabl
et, e
quiv
alen
t to
60m
g ir
on +
40
0mcg
folic
aci
d
76m
ultip
le m
icro
nutr
ient
ssa
chet
UN
ICEF
app
rove
d
77re
tinol
(vi
tam
in A
)ta
blet
/ cap
sule
50,0
00 IU
; 100
,000
IU; 2
00,0
00 IU
(a
s pa
lmita
te)
78zi
nc s
ulph
ate
disp
ersi
ble
tabl
et20
mg
79B
com
plex
tabl
etD
RA
P ap
prov
ed
80m
ultiv
itam
ins
tabl
etD
RA
P ap
prov
ed
Q
Der
mat
olog
ical
s81
benz
yl b
enzo
ateò
ªlo
tion
5%, 2
5%
82ca
lam
ineª
lotio
n15
%
83hy
droc
ortis
oneª
crea
m1%
84po
lym
yxin
B (
sulp
hate
) +
ba
citr
acin
zin
coi
ntm
ent
10,0
00 IU
/g +
500
IU/g
85
silv
er s
ulph
adia
zineò
crea
m1%
R
Oxy
toci
c m
edic
ines
86er
gom
etri
ne (
hydr
ogen
mal
eate
)ªin
ject
ion
200m
cg in
1m
l
87m
isop
rost
olta
blet
200m
cg
88ox
ytoc
inin
ject
ion
10 IU
in 1
-ml
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
S
Con
trac
eptiv
es
89co
ndom
s
90et
hyny
lest
radi
olª
+
nore
this
tero
neª
C
O p
ills
35m
cg +
1m
g
91le
vono
rges
trelª
PO
pill
s30
mcg
92co
pper
T/m
ultil
oad
IUC
D
93 m
edro
xypr
oges
tero
ne a
ceta
te
(DM
PA)
inje
ctio
n15
0mg
/1m
l
94no
reth
iste
rone
ena
ntat
ein
ject
ion
200m
g/m
l in
1ml
T
Vacc
ines
and
ser
a95
BCG
vac
cine
WH
O-a
ppro
ved/
as p
er
natio
nal E
PI p
rogr
am
96D
PT v
acci
ne
97he
patit
is v
acci
ne
98m
easl
es v
acci
ne
99po
lio v
acci
ne
(OPV
tri
vale
nt)/
IPV
oral
/ inj
ectio
n
100
pent
aval
ent
vacc
ine
101
pneu
moc
occa
l vac
cine
102
teta
nus
toxo
id
103
anti-
rabi
es v
acci
ne (
PVRV
)si
ngle
-dos
e vi
al
104
anti-
snak
e ve
nom
ser
um
ESSENTIAL MEDICINES LIST | 35 34 | ESSENTIAL MEDICINES LIST
EML FOR BHUsEML FOR BHUs
BH
Us
BH
Us
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
U
Ant
isep
tics/
di
sinf
ecta
nts
105
povi
done
-iodi
neso
lutio
n10
% w
/v
Onl
y ch
lorin
e-ba
sed
com
poun
d in
sta
ble
dry
gran
ular
form
106
halo
gena
ted
natr
ium
ph
osph
ate
pow
der
100g
ms
107
chlo
rine
-bas
e co
mpo
und
pow
der
(0 .1
% a
vaila
ble
chlo
rine
)
for
solu
tion
108
chlo
rhex
idin
e +
cet
erim
ide
solu
tion
1 .5%
w/v
+ 1
5% w
/v
Ant
isep
tics
for
cor
d ca
re10
9ch
lorh
exid
ine
digl
ucon
ate
(7 .1
%)
for
cord
car
eso
lutio
n, g
eleq
uiva
lent
to
4% c
hlor
hexi
dine
V
Dis
posa
ble
supp
lies
110
syri
nge
(aut
odis
able
)st
erile
pac
ks1c
c an
d 5c
c
111
IV s
ets
(DR
AP
appr
oved
)st
erile
pac
ks
112
IV c
anul
a (D
RA
P ap
prov
ed)
ster
ile p
acks
16G
, 20G
, 24G
113
adhe
sive
tap
e (h
ypoa
llerg
enic
)ro
ll1
inch
, 2 in
ch
114
surg
ical
gau
ze32
pix
, 40
M
115
cott
on b
anda
gero
ll6 .
5cm
x 2
m
116
abso
rben
t co
tton
woo
lpa
ck50
0gm
117
exam
inat
ion
glov
espa
irs
box
of 1
00 (
smal
l, m
ediu
m, a
nd
larg
e) [
1:2:
1]
118
ster
ile s
urgi
cal g
love
spa
irs
7, 7
½
119
silk
sut
ures
ster
ile p
acks
0, 1
/0, 2
/0, 3
/0, 4
/0
120
face
mas
ks d
ispo
sabl
e
121
bloo
d la
ncet
sst
erile
pac
ks
122
slid
es
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
123
clea
n de
liver
y ki
tsst
erile
pac
ks
• 1
bath
soa
p, 5
0 gr
am w
rapp
ed
• 1
apro
n
• 2
pape
r to
wel
• 2
pair
s of
late
x ex
amin
atio
n gl
oves
(M
)
• 1
plas
tic u
nder
shee
t (a
bout
one
sq
uare
met
er)
• 1
unde
rpad
60
cm x
90
cm
• 2
alco
hol p
ads
• 2
pack
s of
spo
nges
(4
spon
ges)
• 1
ster
ile b
ulb
suck
er
• 2
ster
ile u
mbi
lical
cor
d cl
amp
• 1
ster
ile s
urgi
cal b
lade
• 2
cott
on t
hrea
d (c
ord
ties)
• 1
mat
erni
ty p
ad
• 1
whi
te p
oly
bag
for
disp
osal
• 1
unbl
each
ed d
igni
ty d
rape
• 1
inst
ruct
ion
shee
t
ESSENTIAL MEDICINES LIST | 37 36 | ESSENTIAL MEDICINES LIST
EML FOR BHUs
BH
Us
EMERGENCY TRAY FOR BHU
Sr# Name of Item Strength Quantity
1 injection tranexamic acid 250mg/5ml 10
2 injection atropine 1mg/1ml 10
3 injection adrenaline 0 .1mg/ml 10
4 injection diazepam 5mg/ml 10
5 injection diclofenac sodium 25mg/ml 10
6 injection pheniramine (maleate) 22 .7mg/2ml 10
7 injection hydrocortisone sodium 100mg 1
8 injection lidocaine 2% w/v 5
9 water for injection 5ml 5
10 injection ringer lactate 1,000ml 10
11 injection normal saline 1,000ml 10
12 glyceryl trinitrate sublingual 500mcg 50
13 isosorbide dinitrate sublingual 5mg 10
14 lidocaine gel 1
15 cotton roll BPC 500gms 1
16 compression bandage BPC 5
17 D/S 5 cc 30
18 IV set 20
19 IV cannula 18G, 20G, 22G, 24G 20 (1:2:2:1)
20 silk sutures sterile packs 0, 1/0, 2/0 10
21 ETT (3mm, 3 .5mm, 4mm, 7 .5mm, 8mm) 10
22 Foley catheter All sizes (10 F to 28 F) 12
23 NG tube (14–18 Fr, infant/child: 10–14 Fr) 10
24 NG tube (14–18 Fr, infant/child: 10–14 Fr) 10
EML FOR RHCs
ª Primarily indicates similar clinical performance within a pharmacological class.
ò Indicates that the medicine has an age or weight restriction.
© Signifies a specific indication for restricting its use for children.
ESSENTIAL MEDICINES LIST | 39
EML FOR RHCs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
A
Ane
sthe
tics
loca
l
1
lidoc
aine
(hy
droc
hlor
ide)ª
vial
/am
poul
e5%
(hy
droc
hlor
ide)
in 2
ml a
mpo
ule
to b
e m
ixed
with
7 .5
% g
luco
se
solu
tion
topi
cal f
orm
s2%
gel
, 4%
sol
utio
n
2lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
inje
ctio
n2%
+ 1
:200
000
3lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
dent
al c
artr
idge
2% +
1:8
0 00
0
BA
nalg
esic
s op
ioid
4m
orph
ine
(sul
phat
e or
hy
droc
hlor
ide)
ampo
ule
10m
g/1m
l
5pe
thid
ine
(hyd
roch
lori
de)
ampu
le50
mg/
ml i
n 2m
l
C
Ana
lges
ics/
NSA
IDs
6ac
etyl
salic
ylic
aci
d (d
ispe
rsib
le)
tabl
et30
0mg
7m
efen
amic
aci
dta
blet
250m
g
susp
ensi
on50
mg/
5ml
8di
clof
enac
(so
dium
)ta
blet
50m
g
ampu
le75
mg
in 3
ml
9ib
upro
fenò
tabl
et20
0mg,
400m
g
syru
p20
0mg/
5ml
10pa
race
tam
ol
tabl
et50
0mg
inje
ctio
n15
0mg/
ml
syru
p12
5mg/
5ml
supp
osito
ry10
0mg
DA
nti-A
llerg
ics
and
med
icin
es u
sed
in
anap
hyla
xis
11ª
chlo
rphe
nira
min
e (h
ydro
gen
mal
eate
)ò
tabl
et4m
g
inje
ctio
n10
mg/
ml
syru
p©2m
g/5m
l
ESSENTIAL MEDICINES LIST | 41 40 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
12de
xam
etha
sone
(d
isod
ium
pho
spha
te)
inje
ctio
n4m
g/m
l
tabl
et0 .
5mg
13ep
inep
hrin
e (a
dren
alin
e)am
pule
1mg
/ml
14hy
droc
ortis
one
(sod
ium
su
ccin
ate)
inje
ctio
n10
0mg,
250m
g
15lo
ratid
ine
tabl
et10
mg
syru
p1m
g/m
l
16pr
edni
solo
neª
tabl
et5m
g
E
Ant
idot
es a
nd o
ther
su
bsta
nces
use
d in
po
ison
ings
17at
ropi
ne (
sulfa
te)ò
ampu
le1m
g in
1m
l
18ch
arco
al a
ctiv
ated
pow
der
19di
azep
amin
ject
ion
10m
g
20m
ethy
lthio
nini
um c
hlor
ide
(met
hyle
ne b
lue)
ampu
le10
mg/
ml i
n 10
ml
21na
loxo
ne (
hydr
ochl
orid
e)am
pule
400m
cg in
1m
l
FA
nti-E
pile
ptic
s22
carb
amaz
epin
e ta
blet
200m
g
syru
p10
0mg/
5ml
Fo
r ec
lam
psia
onl
y23
mag
nesi
um s
ulph
ate
inje
ctio
n50
0mg/
ml
24ph
enob
arbi
tal (
sodi
um)
tabl
et30
mg
inje
ctio
n20
0mg/
ml
25ph
enyt
oin
(sod
ium
)ta
blet
100m
g
G
Ant
i-Hel
min
thic
26al
bend
azol
e ta
blet
200m
g
syru
p10
0mg/
5ml
27m
eben
dazo
le (
chew
able
)ta
blet
500m
g (w
ith c
autio
n on
ly fo
r ad
ults
)
28py
rant
el (
pam
oate
)ta
blet
250m
g
syru
p25
0mg/
5ml
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
H
Ant
i-Fun
gal
29
clot
rim
azol
e
vagi
nal c
ream
1%
vagi
nal t
able
t10
0mg,
500m
g
topi
cal c
ream
1% w
/w
30ny
stat
in
tabl
et50
0,00
0 IU
drop
s©10
0,00
0 IU
/ml
pess
ary
100,
000
IU
I
Ant
i-Inf
ectiv
es
Ant
ibio
tics/
an
timic
robi
als
31
amox
icill
in (
trih
ydra
te)
caps
ule/
tab
let
250m
g, 50
0mg
(pre
fera
bly
disp
ersi
ble
tabl
et)
syru
p©12
5mg,
250m
g/5m
l
inje
ctio
n25
0mg,
500m
g
32am
pici
llin
(sod
ium
)
caps
ule
250m
g, 50
0mg
syru
p©12
5mg,
250m
g/5m
l
inje
ctio
n50
0mg
and
1g
33az
ithro
myc
inª
caps
ule
250m
g, 50
0mg
susp
ensi
on12
5mg/
5ml i
n 22
.5m
l
34be
nzat
hine
pen
icill
inin
ject
ion©
0 .6m
IU, 1
.2m
IU
Onl
y fo
r ep
idem
ic m
enin
gitis
35ch
lora
mph
enic
ol
caps
ule
250m
g
(pal
mita
te)
syru
p12
5mg/
5ml
(sod
ium
suc
cina
te)
inje
ctio
n1g
m
Onl
y lis
ted
for
singl
e-do
se tr
eatm
ent o
f un
com
plica
ted
ano-
geni
tal
gono
rrhe
a
36ce
fixim
e* (
trih
ydra
te)
caps
ule
400m
g
37ci
profl
oxac
in (h
ydro
chlo
ride
)ªta
blet
250m
g, 50
0mg
38co
trim
oxaz
oleò
tabl
et©
400m
g +
80m
g
(sul
fam
etho
xazo
le +
tr
imet
hopr
im)
syru
p©20
0mg
+ 4
0mg/
5ml
39do
xycy
clin
e (h
ycla
te)ò
caps
ule
100m
g
ESSENTIAL MEDICINES LIST | 43 42 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
40ge
ntam
icin
(su
lfate
)ªin
ject
ion
40m
g, 80
mg
41m
etro
nida
zoleª
(b
enzo
ate)
tabl
et20
0mg,
400m
g
syru
p20
0mg/
5ml
infu
sion
5mg/
ml i
n 10
0ml
42ni
trof
uran
toin
ta
blet
100m
g
43pr
ocai
ne b
enzy
lpen
icill
in
inje
ctio
n1
m IU
; 3
m IU
44ph
enox
ymet
hy/p
enic
illin
(p
otas
sium
)ta
blet
250m
g, 50
0mg
syru
p12
5mg/
5ml
JA
nti-T
uber
culo
sis
med
icin
es45
etha
mbu
tol
tabl
et40
0mg
oral
liqu
id©
25m
g/m
l
As p
er T
B co
ntro
l pro
gram
gu
idel
ines
46is
onia
zid
tabl
et/s
yrup
©50
mg,
100m
g, 30
0mg
47py
razi
nam
ide
tabl
et50
0mg
48ri
fam
pici
nca
psul
e/sy
rup©
150m
g, 30
0mg,
450m
g, 60
0mg
49st
rept
omyc
inin
ject
ion
1gm
50et
ham
buto
l + is
onia
zid
tabl
et40
0mg
+ 1
50m
g
51is
onia
zid
+ r
ifam
pici
nta
blet
75m
g +
150
mg;
150m
g +
300
mg
52is
onia
zid
+ p
yraz
inam
ide
+
rifa
mpi
cin
tabl
et75
mg
+ 4
00m
g +
150
mg
53ri
fam
pici
n +
ison
iazi
d +
py
razi
nam
ide
+ e
tham
buto
lta
blet
150m
g +
75m
g +
40
0mg
+ 2
75m
g
54et
ham
buto
l + is
onia
zid
+
rifa
mpi
cin
tabl
et27
5mg
+ 7
5mg
+ 1
50m
g
K
Ant
i-Dia
betic
s55
glib
encl
amid
eta
blet
5mg
56m
etfo
rmin
(hy
droc
hlor
ide)
tabl
et50
0mg
57in
sulin
reg
ular
inje
ctio
n10
0 IU
/ml
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
58in
sulin
com
pin
ject
ion
30%
+ 7
0% w
/v
L
Ant
imal
aria
l59
chlo
roqu
ine
(pho
spha
te o
r su
lfate
)ta
blet
150m
g
For V
ivax
60pr
imaq
uine
(di
phos
phat
e)ta
blet
15m
g
For
falci
paru
m61
sulp
hado
xine
+ p
yrim
etha
min
e co
-blis
ter/
com
bine
d th
erap
yta
blet
500m
g +
25m
g
To b
e us
ed in
com
bina
tion
(co-
blist
er)
62
arte
suna
te +
sul
phad
oxin
e an
d py
rim
etha
min
eta
blet
co-b
liste
r of
(6+
2) t
able
t, 2
larg
e ta
blet
s–ea
ch h
as s
ulfa
doxi
ne 5
00m
g U
.S .P .
+ p
yrim
etha
min
e 25
mg
U .S
.P—
6 sm
all t
able
ts, e
ach
has
arte
suna
te 5
0mg
U .S
.P .
Man
agem
ent o
f sev
ere
mal
aria
arte
suna
te +
sul
phad
oxin
e an
d py
rim
etha
min
eta
blet
co-b
liste
r of
(6
+ 3
) ta
blet
—3
larg
e ta
blet
, eac
h ha
s su
lfado
xine
50
0mg
U .S
.P . +
pyr
imet
ham
ine
25m
g U
.S .P .
—6
smal
l tab
let,
each
tab
let
has
arte
suna
te 1
00m
g U
.S .P .
63ar
tem
ethe
rin
ject
ion
40m
g/m
l
M
GIT
med
icin
es64
hyos
cine
(bu
tylb
rom
ide)
inje
ctio
n20
mg/
ml
tabl
et10
mg
65ph
loro
gluc
inol
tabl
etph
loro
gluc
inol
80m
g +
tr
imet
hylp
hlor
oglu
cino
l 80m
g
66m
etoc
lopr
amid
e
(hyd
roch
lori
de)ò
tabl
et10
mg
syru
p5m
g/5m
l
inje
ctio
n5m
g/m
l
67om
epra
zoleª
caps
ule
10m
g, 20
mg,
40m
g
68ra
nitid
ine
inje
ctio
n25
mg/
ml i
n 2m
l
tabl
et15
0mg,
250m
g
ESSENTIAL MEDICINES LIST | 45 44 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
69
alum
iniu
m h
ydro
xide
+
mag
nesi
um t
risi
licat
eta
blet
250m
g +
500
mg
Reco
mm
ende
d in
co
mbi
natio
n w
ith z
inc
sulp
hate
20m
g di
sper
sible
ta
blet
for
acut
e di
arrh
ea
70O
RS
(low
osm
olar
ity)
sach
et
dry
mix
ture
(lo
w o
smol
arity
fo
rmul
a) in
sac
het
for
1 lit
er o
f so
lutio
n, e
ach
sach
et c
onta
ins
gluc
ose
anhy
drou
s 13
.5gm
B .P .
, tr
isod
ium
citr
ate
dihy
drat
e 2 .
9gm
B .
P ., p
otas
sium
chl
orid
e1 .5
gm B
.P .,
sodi
um c
hlor
ide
2 .6g
m B
.P .
71bi
saco
dyl
tabl
et5m
g
72gl
ycer
insu
ppos
itory
N
Car
diov
ascu
lar
med
icin
es73
glyc
eryl
tri
nitr
ate
subl
ingu
al50
0mcg
74is
osor
bide
din
itrat
eª
subl
ingu
al5m
g
75am
lodi
pine
(be
syla
te)
tabl
et2 .
5mg,
5mg
For
seve
re p
regn
ancy
in
duce
d hy
pert
ensio
n
(PIH
) onl
y76
met
hyld
opa
tabl
et25
0mg,
500m
g
inje
ctio
n25
0mg
For
seve
re P
IH o
nly
77hy
droc
hlor
othi
azid
eªin
ject
ion
20m
g
tabl
et25
mg,
50m
g
78en
alap
ril (
mal
eate
)ta
blet
5mg,
10m
g
79at
enol
olta
blet
5mg,
10m
g, 25
mg
80
furo
sem
ideª
tabl
et20
mg,
40m
g
inje
ctio
n10
mg
O
Oxy
toci
c m
edic
ines
81er
gom
etri
ne
(hyd
roge
n m
alea
te)ª
inje
ctio
n20
0mcg
in 1
ml
82m
isop
rost
olta
blet
200m
cg
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
83ox
ytoc
inin
ject
ion
10 IU
in 1
ml
P
Res
pira
tory
med
icin
es
84sa
lbut
amol
(su
lfate
)ªta
blet
2mg
and
4mg
inha
ler
100m
cg p
er d
ose
85
amm
oniu
m c
hlor
ide
+
chlo
rofo
rm +
men
thol
+
diph
enhy
dram
ine
+ s
odiu
m
citr
ate
antit
ussi
ve e
xpec
tora
nt13
1 .5m
g/5m
l + 2
2mg/
5ml +
1m
g/5m
l + 1
3 .5m
g/5m
l + 5
5mg/
5ml
86am
inop
hylli
nein
ject
ion
25m
g/m
l
Q
Oph
thal
mic
/EN
T
87bo
rogl
ycer
ine
ear
drop
s
(onl
y fo
r w
ax r
emov
ing)
40 .0
0%
88po
lym
yxin
B s
ulph
ate
+
ligno
cain
eea
r dr
ops
each
ml c
onta
ins
Poly
myx
in
B (S
ulph
ate)
:100
0IU
/m
l,Lig
noca
ine:
50m
g/m
l]; 5
ml p
last
ic
bott
le
89ch
lora
mph
enic
ol
eye
drop
s1%
w/v
, 0 .5
% w
/v
90ci
profl
oxac
inª
(h
ydro
chlo
ride
)ey
e/ea
r dr
ops
0 .3%
w/v
91te
trac
yclin
e (h
ydro
chlo
ride
)ªey
e oi
ntm
ent
1%
92xy
lom
etaz
olin
eò ª
nasa
l dro
ps0 .
05%
R
I/V In
fusi
ons
93pl
asm
a ex
pand
erin
fusi
onde
xtra
n 6%
w/v
, glu
cose
5%
w/v
Plas
ma
subs
titut
es94
gluc
ose/
dext
rose
infu
sion
5%, 1
0,%
ampu
le25
%
95no
rmal
sal
ine
infu
sion
0 .9%
96de
xtro
se +
sal
ine
infu
sion
5% +
0 .9
% w
/v
ESSENTIAL MEDICINES LIST | 47 46 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
97R
inge
r la
ctat
eªin
fusi
on
infu
sion
1,00
0ml c
onta
ins
calc
ium
ch
lori
de 0
.2gm
U .S
.P .; p
otas
sium
ch
lori
de 0
.3gm
U .S
.P .; s
odiu
m
chlo
ride
6gm
U .S
.P .; 3
.1gm
sod
ium
la
ctat
e U
.S .P .
, ste
rile
wat
er fo
r in
ject
ion
98po
tass
ium
chl
orid
eso
lutio
n11
.2%
in 2
0ml a
mpo
ule
99so
dium
bic
arbo
nate
inje
ctio
n1 .
4% is
oton
ic
100
wat
er fo
r in
ject
ion
ampu
le5m
l, 10
ml
S
Vita
min
s an
d m
iner
als
101
asco
rbic
aci
dta
blet
50m
g, 10
0mg,
500m
g
102
calc
ium
glu
cona
tein
ject
ion
100m
g/m
l in
10-m
l
103
calc
ium
lact
ate
tabl
et50
0mg,
1gm
104
calc
ium
chl
orid
ein
ject
ion
200m
g/m
l
105
ergo
calc
ifero
l (vi
tam
in D
)ªta
blet
1 .25
mg
(50,
000
IU)
106
ferr
ous
salt
(fum
erat
e)ta
blet
equi
vale
nt t
o 60
mg
iron
syru
peq
uiva
lent
to
25m
g/m
l iro
n
107
folic
aci
d ta
blet
1mg,
5mg
108
ferr
ous
salt
+ fo
lic a
cid
tabl
et (
DR
AP
appr
oved
)ta
blet
, equ
ival
ent
to 6
0mg
iron
+
400m
cg fo
lic a
cid
109
mul
tiple
mic
ronu
trie
nts
sach
et
110
retin
ol (
vita
min
A)
tabl
et/c
apsu
le50
,000
IU; 1
00,0
00 IU
; 200
,000
IU
(as
palm
itate
)
111
zinc
sul
phat
edi
sper
sibl
e ta
blet
20m
g
112
vita
min
Kin
ject
ion
10m
g
113
B co
mpl
exta
blet
114
mul
tivita
min
sta
blet
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
T
Der
mat
olog
ical
s11
5be
nzyl
ben
zoat
eò ª
lotio
n5%
, 25%
116
perm
ethr
incr
eam
, lot
ion
5% w
/w
117
cala
min
eªlo
tion
15%
118
coal
tar
lotio
n5%
119
clob
etas
ol (
prop
iona
te)
crea
m0 .
05%
w/w
120
hydr
ocor
tison
eªcr
eam
1%
121
poly
myx
in B
(su
lpha
te)
+
baci
trac
in z
inc
oint
men
t10
,000
IU/g
+ 5
00 IU
/g
122
silv
er s
ulph
adia
zineò
crea
m1%
U
Con
trac
eptiv
es
123
cond
oms
124
ethy
nyle
stra
diolª
+
nore
this
tero
neª
C
O p
ills
35m
cg +
1m
g
125
levo
norg
estr
elª
PO
pill
s30
mcg
126
levo
norg
estr
el
EC p
ills
750
mcg
(pa
ck o
f 2)
127
copp
er T
/mul
tiloa
dIU
CD
128
DM
PA (
med
roxy
prog
este
rone
ac
etat
e)in
ject
ion
150m
g/1m
l
129
nore
this
tero
ne e
nant
ate
inje
ctio
n20
0mg/
ml i
n 1m
l
130
estr
adio
l cyp
iona
te +
m
edro
xypr
oges
tero
ne a
ceta
tein
ject
ion
5mg
+ 2
5mg
VVa
ccin
es a
nd s
era
131
BCG
vac
cine
WH
O a
ppro
ved/
as p
er n
atio
nal E
PI
prog
ram
131
DPT
vac
cine
132
polio
vac
cine
(O
PV t
riva
lant
)/IP
Vor
al/ i
njec
tion
133
hepa
titis
vac
cine
ESSENTIAL MEDICINES LIST | 49 48 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
134
mea
sles
vac
cine
135
teta
nus
toxo
id
136
pent
aval
ant
vacc
ine
137
pneu
moc
occa
l vac
cine
138
anti-
rabi
es v
acci
ne (
PVRV
)si
ngle
-dos
e vi
al
139
anti-
snak
e ve
nom
ser
um
WM
isce
llane
ous
140
tran
exam
ic a
cid
inje
ctio
n25
0mg,
500m
g /5
ml
caps
250m
g, 50
0mg
XA
nxio
lytic
s14
1al
praz
olam
tabl
et0 .
5mg
142
diaz
epam
tabl
et2m
g
Y
Ant
isep
tics/
dis
infe
ctan
ts14
3po
vido
ne-io
dine
solu
tion
10%
w/v
Onl
y ch
lorin
e-ba
sed
com
poun
d in
sta
ble
dry
gran
ular
form
143
halo
gena
ted
natr
ium
ph
osph
ate
pow
der
100g
m
144
chlo
rine
bas
e co
mpo
und
pow
der
(0 .1
% a
vaila
ble
chlo
rine
) fo
r so
lutio
n
145
chlo
rhex
idin
e +
cet
erim
ide
solu
tion
1 .5%
w/v
+ 1
5% w
/v
Ant
isep
tics
for
cord
car
e14
6ch
lorh
exid
ine
digl
ucon
ate
(7 .1
%)
for
cord
car
eso
lutio
n, g
eleq
uiva
lent
to
4% c
hlor
hexi
dine
Z
Dis
posa
ble
supp
lies
147
syri
nge
(aut
odis
able
)st
erile
pac
ks1c
c, 5c
c
148
IV s
ets
(DR
AP
appr
oved
)st
erile
pac
ks
149
scal
p ve
in s
et (
DR
AP
appr
oved
)st
erile
pac
ks
150
volu
met
ric
cham
ber
(IV
bure
tte)
ster
ile p
acks
100m
l siz
e
151
IV c
anul
a (D
RA
P ap
prov
ed)
ster
ile p
acks
18G
, 20G
, 22G
, 24G
152
adhe
sive
tap
e (h
ypoa
llerg
enic
)ro
ll1
inch
, 2 in
ch
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
153
ster
ile g
auze
dre
ssin
g7 .
5 x
7 .5
cm (
10 p
ly)
154
liqui
d pa
raffi
n ga
uze
ster
ile p
acks
155
cott
on b
anda
gero
ll6 .
5cm
x 2
m
156
abso
rben
t co
tton
woo
lpa
ck50
0gm
157
crep
e ba
ndag
e7 .
5, 1
0 cm
x 2
.7m
158
exam
inat
ion
glov
espa
irs
box
of 1
00
(sm
all,
med
ium
, and
larg
e si
ze)
[1:2
:1]
159
ster
ile s
urgi
cal g
love
spa
irs
6, 6
½, 7
, 7½
160
silk
sut
ures
ste
rile
12/p
ack
0, 1
/0, 2
/0, 3
/0, 4
/0
161
chro
mic
cat
gut
ster
ilest
erile
pac
ks0,
1/0
, 2/0
, 3/0
, 4/0
162
face
mas
ks d
ispo
sabl
e
163
bloo
d la
ncet
sst
erile
pac
ks
164
slid
es
165
air
way
set
of 3
adul
t/pe
diat
ric
166
endo
trac
heal
tub
est
erile
pac
ksse
t of
12
167
resu
scita
tor
bag
with
mas
kad
ult/
pedi
atri
c
168
naso
gast
ric
tube
adul
t/pe
diat
ric
ESSENTIAL MEDICINES LIST | 51 50 | ESSENTIAL MEDICINES LIST
EML FOR RHCsEML FOR RHCs
RH
Cs
RH
Cs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
169
clea
n de
liver
y ki
tsst
erile
pac
ks
• 1
bath
soa
p, 5
0 gr
am w
rapp
ed
• 1
apro
n
• 2
pap
er t
owel
• 2
pai
rs o
f lat
ex e
xam
inat
ion
glov
es (
M)
• 1
plas
tic u
nder
shee
t (a
bout
one
sq
uare
met
er)
• 1
unde
rpad
60
cm x
90
cm
• 2
alc
ohol
pad
s
• 2
pac
ks o
f spo
nges
(4
spon
ges)
• 1
ster
ile b
ulb
suck
er
• 2
ste
rile
um
bilic
al c
ord
clam
p
• 1
ster
ile s
urgi
cal b
lade
• 2
cot
ton
thre
ad (
cord
tie
s)
• 1
mat
erni
ty p
ad
• 1
whi
te p
oly
bag
for
ispo
sal
• 1
unbl
each
ed d
igni
ty d
rape
• 1
inst
ruct
ion
shee
t
EMERGENCY TRAY FOR RHC
Sr# Name of Item Strength Quantity
1 injection dobutamine 50mg/ml 5
2 injection tranexamic acid 250mg/5ml 10
3 injection furosemide 10mg/ml 10
4 injection calcium gluconate 100mg/ml in 10ml 10
5 injection dimenhydrinate 50mg/ml 10
6 injection sodium bicarbonate 8 .4% w/v, 25ml 10
7 injection potassium chloride 11 .2% in 20ml ampoule 5
8 injection atropine 1mg/1ml 10
9 injection adrenaline 0 .1mg/ml 10
10 injection diazepam 5mg/ml 10
11 injection diclofenac sodium 25mg/ml 10
12 injection plasma expander 500ml 5
13 injection hydrocortisone sodium 100mg and 250mg 20 (1:1)
14 injection ranitidine 25mg/ml 10
15 injection aminophylline 25mg/ml 10
16 injection lidocaine 2% w/v, 10ml 10
17 water for injection 5ml 5
18 injection 25% DW 25ml ampoule 10
19 Ringer’s lactate infusion 1000ml 10
20 dextrose infusion 10%, 500ml 10
21 normal saline infusion 1,000ml 10
22normal saline with dextrose
infusion5%, 1,000ml 10
23 lidocaine gel 5
24 cotton roll BPC 500gms 5
25 cotton bandage BPC 4 inch, 6 inch 24
26 D/S (AD) 5 cc 10
27 D/S 10cc 5
28 D/S 1cc 5
29 D/S 20cc 1
ESSENTIAL MEDICINES LIST | 53 52 | ESSENTIAL MEDICINES LIST
EML FOR RHCs
RH
Cs
EMERGENCY TRAY FOR RHC
Sr# Name of Item Strength Quantity
30 volumetric chamber (IV burette) 5
31 IV set 45
32 IV cannula 16G, 18G, 20G, 22G, 24G 25 (1:1:2:2:1)
33 ETT (3mm, 3 .5mm, 4mm, 7 .5mm, 8mm) 10
34 Foley catheter all sizes (10 F to 28 F) 10
35 NG tube (14–18 Fr, infant/child: 10–14 Fr) 12
EML FOR THQs
ª Primarily indicates similar clinical performance within a pharmacological class.
ò Indicates that the medicine has an age or weight restriction.
© Signifies a specific indication for restricting its use for children.
ESSENTIAL MEDICINES LIST | 55
EML FOR THQs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
A
Ane
sthe
tics
gene
ral
1ha
loth
ane/
isofl
uran
ein
hala
tion
2ni
trou
s ox
ide
inha
latio
n
3ox
ygen
(m
edic
inal
gas
) cy
linde
rin
hala
tion
4ke
tam
ine
(hyd
roch
lori
de)
inje
ctio
n50
mg
/ml i
n 10
ml
5
thio
pent
al s
odiu
min
ject
ion
10m
g/m
l, 20
mg/
ml
B
Mus
cle
rela
xant
s6
neos
tigm
ine
(met
ilsul
fate
)in
ject
ion
2 .5m
g in
1m
l
(bro
mid
e)ta
blet
15m
g
7
suxa
met
honi
um (
chlo
ride
)am
poul
e50
mg/
ml i
n 2m
l
C
Ane
sthe
tics
loca
l8
bupi
vaca
ine
(hyd
roch
lori
de)ª
vial
0 .25
%; 0
.5%
inje
ctio
n fo
r sp
inal
ane
sthe
sia
ampo
ule
(5m
g/m
l) 0 .
5% in
4m
l
9lid
ocai
ne (
hydr
ochl
orid
e)ª
vial
5% (
hydr
ochl
orid
e) in
2ml a
mpo
ule
to b
e m
ixed
with
7 .5
%
gluc
ose
solu
tion
topi
cal f
orm
s2%
gel
, 4%
sol
utio
n
10lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
inje
ctio
n2%
+ 1
:200
,000
11lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
dent
al c
artr
idge
2% +
1:8
0,00
0
Com
plem
enta
ry li
st
12ep
hedr
ine
(hyd
roch
lori
de)
ampo
ule .
30m
g in
1m
l
D
Ana
lges
ics
O
pioi
d/ce
ntra
l act
ing
13m
orph
ine
(sul
phat
e or
hy
droc
hlor
ide)
ampo
ule
10m
g in
1m
l
14pe
thid
ine
(hyd
roch
lori
de)
ampu
le50
mg/
ml i
n 2m
l
15na
lbup
hine
(H
Cl)
inje
ctio
n10
mg/
ml,
20m
g/m
l
16pe
ntaz
ocin
inje
ctio
n30
mg/
ml
EA
nalg
esic
s/N
SAID
s17
acet
ylsa
licyl
ic a
cid
(dis
pers
ible
)di
sper
sibl
e ta
blet
300m
g
ESSENTIAL MEDICINES LIST | 57 56 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
18di
clof
enac
(so
dium
)
tabl
et50
mg
ampu
le75
mg
in 3
ml
gel
3% w
/w
19ib
upro
fenò
tabl
et20
0, 4
00m
g
gel
10%
w/w
syru
p20
0mg/
5ml
20na
prox
enta
blet
250m
g, 50
0mg
21pa
race
tam
ol
tabl
et50
0mg
syru
p12
5mg/
5ml
inje
ctio
n15
0mg/
ml
supp
osito
ry10
0mg
FM
edic
ines
to
trea
t go
ut22
allo
puri
nol
tabl
et10
0mg
and
300m
g
G
Ant
i-Alle
rgic
s an
d m
edic
ines
use
d in
an
aphy
laxi
s23
chlo
rphe
nira
min
e (h
ydro
gen
mal
eate
)ò ª
tabl
et4m
g
inje
ctio
n10
mg/
ml
syru
p©2m
g/5m
l
24lo
rata
dine
tabl
et10
mg
syru
p1m
g/m
l
25ce
tiriz
ine
tabl
et10
mg
syru
p5m
g/5m
l
26pr
omet
hazi
ne (
HC
l)
tabl
et25
mg
syru
p25
mg/
5ml
inje
ctio
n25
mg/
ml i
n 2m
l
27
dexa
met
haso
ne (
diso
dium
ph
osph
ate)
inje
ctio
n4m
g/m
l
tabl
et0 .
5mg
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
28
epin
ephr
ine
(adr
enal
ine)
ampu
le1m
g /m
l
29
hydr
ocor
tison
e (s
odiu
m
succ
inat
e)in
ject
ion
100m
g, 25
0mg
30pr
edni
solo
neª
tabl
et5m
g
H
Ant
idot
es a
nd o
ther
su
bsta
nces
use
d in
po
ison
ings
31at
ropi
ne (
sulfa
te)ò
ampu
le1m
g in
1m
l
32ch
arco
al a
ctiv
ated
pow
der
33m
ethy
lthio
nini
um c
hlor
ide
(met
hyle
ne b
lue)
ampu
le10
mg/
ml i
n 10
ml
34na
loxo
ne (
hydr
ochl
orid
e)am
pule
400
mcg
in 1
ml
I A
nti-E
pile
ptic
s A
nti-C
onvu
lsiv
es
For
ecle
mps
ia o
nly
35ca
rbam
azep
ine
tabl
et20
0mg
syru
p10
0mg/
5ml
36m
agne
sium
sul
phat
ein
ject
ion
500m
g/m
l
37ph
enob
arbi
tal (
sodi
um)
tabl
et30
mg
inje
ctio
n20
0mg
/ml
38ph
enyt
oin
(sod
ium
)ta
blet
100m
g
syru
p30
mg/
5ml
J A
ntib
iotic
s/
antim
icro
bial
s39
amox
icill
in (
trih
ydra
te)
(pre
fera
bly
disp
ersi
ble
tabl
et)
caps
ule/
tab
let
250m
g, 50
0mg
pow
der
for
susp
ensi
on©
125m
g, 25
0mg/
5ml
inje
ctio
n25
0mg,
500m
g
40am
pici
llin
(sod
ium
)
caps
ule
250m
g, 50
0mg
pow
der
for
susp
ensi
on©
125m
g, 25
0mg/
5ml
inje
ctio
n50
0mg,
1 g
41am
oxic
illin
+ c
lavu
lani
c ac
idta
blet
125m
g am
oxic
illin
+ 3
1 .25
mg
clav
ulan
ic a
cid/
5ml a
nd 2
50m
g am
oxic
illin
+ 6
2 .5m
g cl
avul
anic
ac
id/5
ml
ESSENTIAL MEDICINES LIST | 59 58 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
in
ject
ion
1gm
42be
nzat
hine
pen
icill
inin
ject
ion©
0 .6m
IU, 1
.2m
IU
43cl
oxac
illin
caps
ule
250m
g, 50
0mg
pow
der
for
susp
ensi
on©
125m
g, 25
0mg/
5ml
Onl
y lis
ted
for
singl
e-do
se tr
eatm
ent o
f un
com
plica
ted
ano-
geni
tal
gono
rrhe
a
44ce
fixim
e* (
trih
ydra
te)
caps
ule
400m
g
syru
p10
0mg,
200m
g/5m
l
45ce
ftri
axon
e (s
odiu
m)ò
pow
der
for
inje
ctio
n25
0mg,
500m
g, 1g
m
Onl
y fo
r ep
idem
ic m
enin
gitis
46
chlo
ram
phen
icol
ca
psul
e25
0mg
(pal
mita
te)
syru
p12
5mg/
5ml
(sod
ium
suc
cina
te)
inje
ctio
n1g
m
47ci
profl
oxac
in (h
ydro
chlo
ride
)ªta
blet
250m
g, 50
0mg
48az
ithro
myc
inª
caps
ule
250m
g, 50
0mg
susp
ensi
on12
5mg/
5ml i
n 22
.5m
l
Reco
mm
ende
d in
co
mbi
natio
n re
gim
ens
for
erad
icatin
g H
. pylo
ri in
ad
ult.
49cl
arith
rom
ycin
*ta
blet
500m
g
50cl
inda
myc
in (
hydr
ochl
orid
e)ca
psul
e15
0mg,
300m
g
(pho
spha
te)
inje
ctio
n15
0mg/
ml
51co
trim
oxaz
oleò
tabl
et©
400m
g +
80m
g
(sul
fam
etho
xazo
le +
tr
imet
hopr
im)
syru
p©20
0mg
+ 4
0mg/
5ml
52do
xycy
clin
e (h
ycla
te)ò
caps
ule©
100m
g
syru
p©25
mg/
5ml
53ge
ntam
icin
(su
lfate
)ªin
ject
ion
40m
g, 80
mg
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
54
levo
floxa
cin
tabl
et25
0g, 5
00m
g
55m
etro
nida
zoleª
(b
enzo
ate)
tabl
et20
0mg,
400m
g
inje
ctio
n50
0mg
in 1
00-m
l
syru
p20
0mg/
5ml
56ni
trof
uran
toin
ta
blet
100m
g
57pr
ocai
ne b
enzy
lpen
icill
in
inje
ctio
n1m
IU, 3
m IU
58ph
enox
ymet
hylp
enic
illin
(p
otas
sium
)ta
blet
250m
g, 50
0mg
syru
p12
5mg/
5ml
KA
nti-H
elm
inth
ic59
albe
ndaz
ole
tabl
et20
0mg
syru
p10
0mg/
5ml
60m
eben
dazo
le (
chew
able
)ta
blet
500m
g (w
ith c
autio
n on
ly fo
r ad
ults
)
61py
rant
el (
pam
oate
)ta
blet
250m
g
syru
p25
0mg/
5ml
L
Ant
i-Fun
gal
62cl
otri
maz
ole
vagi
nal c
ream
1%
vagi
nal t
able
t10
0mg,
500m
g
63flu
cona
zoleª
caps
ule
50m
g
inje
ctio
n2m
g/m
l
syru
p50
mg/
5ml
64ny
stat
inta
blet
500,
000
IU
drop
s©10
0,00
0 IU
/ml
M
Ant
i-Tub
ercu
losi
s m
edic
ines
As p
er T
B Co
ntro
l pro
gram
gu
idel
ines
65et
ham
buto
lta
blet
400m
g
oral
liqu
id©
25m
g/m
l
66is
onia
zid
tabl
et/s
yrup
©50
mg,
100m
g, 30
0mg
ESSENTIAL MEDICINES LIST | 61 60 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
67py
razi
nam
ide
tabl
et50
0mg
68ri
fam
pici
nca
ps/s
yrup
©15
0mg,
300m
g, 45
0mg,
600m
g
69st
rept
omyc
inin
ject
ion
1gm
70et
ham
buto
l + is
onia
zid
tabl
et40
0mg
+ 1
50m
g
71is
onia
zid
+ r
ifam
pici
nta
blet
75m
g +
150
mg;
150m
g +
300
mg
72is
onia
zid
+ p
yraz
inam
ide
+
rifa
mpi
cin
tabl
et75
mg
+ 4
00m
g +
150
mg
73ri
fam
pici
n +
ison
iazi
d +
py
razi
nam
ide
+ e
tham
buto
lta
blet
150m
g +
75m
g+
400m
g +
275
mg
74et
ham
buto
l + is
onia
zid
+
rifa
mpi
cin
tabl
et27
5mg
+ 7
5mg
+ 1
50m
g
N
Ant
i-Dia
betic
s75
glib
encl
amid
eta
blet
5mg
76gl
imep
irid
e ta
blet
1mg,
2mg,
3mg
77m
etfo
rmin
(hy
droc
hlor
ide)
tabl
et50
0mg
78in
sulin
reg
ular
inje
ctio
n10
0 IU
/ml
79in
sulin
com
pin
ject
ion
30%
+ 7
0% w
/v
O
Ant
imal
aria
l80
chlo
roqu
ine
(pho
spha
te o
r su
lfate
)ta
blet
150m
g
For
vivax
81pr
imaq
uine
(di
phos
phat
e)ta
blet
15m
g
For
falci
paru
m82
sulp
hado
xine
+ p
yrim
etha
min
eta
blet
500m
g +
25m
g
To b
e us
ed in
com
bina
tion
(co-
blist
er)
83ar
tesu
nate
tabl
et50
mg
Man
agem
ent o
f sev
ere
mal
aria
84ar
tesu
nate
+ s
ulph
adox
ine
+
pyri
met
ham
ine
tabl
et
co-b
liste
r of
(6
+ 2
) ta
blet
—2
larg
e ta
blet
, eac
h ha
s su
lfado
xine
50
0mg
U .S
.P . +
pyr
imet
ham
ine
25m
g U
.S .P
]—6
smal
l tab
lets
, eac
h ha
s ar
tesu
nate
50m
g U
.S .P .
]
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
arte
suna
te +
sul
phad
oxin
e +
py
rim
etha
min
eta
blet
s
co-b
liste
r of
(6
+ 3
) ta
blet
—3
larg
e ta
blet
s, ea
ch h
as s
ulfa
doxi
ne
500m
g U
.S .P .
+ p
yrim
etha
min
e 25
mg
U .S
.P .—
6 sm
all t
able
ts, e
ach
tabl
et
cont
ains
art
esun
ate
100m
g U
.S .P .
85ar
tem
ethe
r*am
pule
80m
g/m
l in
1ml
86ar
tem
ethe
r +
lum
efan
trin
e*ta
blet
©20
mg
+ 1
20m
g
PG
IT m
edic
ines
85hy
osci
ne (
buty
lbro
mid
e)in
ject
ion
20m
g/m
l
tabl
et10
mg
86ph
loro
gluc
inol
tabl
etph
loro
gluc
inol
80m
g +
tr
imet
hylp
hlor
oglu
cino
l 80m
g
87m
etoc
lopr
amid
e
(hyd
roch
lori
de)ò
tabl
et10
mg
syru
p5m
g/5m
l
inje
ctio
n5m
g/m
l
88di
men
hydr
inat
eta
blet
50m
g
89om
epra
zoleª
caps
ule
10m
g, 20
mg,
40m
g
90ra
nitid
ine
inje
ctio
n25
mg/
ml i
n 2m
l
tabl
et15
0mg,
250m
g
91al
umin
ium
hyd
roxi
de +
m
agne
sium
tri
silic
ate
tabl
et25
0mg
+ 5
00m
g
For
trea
tmen
t of a
cute
di
arrh
ea—
in c
ombi
natio
n w
ith z
inc
sulp
hate
20m
g di
sper
sible
tabl
et
92O
RS
(low
osm
olar
ity)
sach
et
dry
mix
ture
(lo
w o
smol
arity
fo
rmul
a) in
sac
het
for
1 lit
er o
f so
lutio
n—ea
ch s
ache
t co
ntai
ns
gluc
ose
anhy
drou
s 13
.5gm
B .P .
, tr
isod
ium
citr
ate
dihy
drat
e 2 .
9gm
B .
P, po
tass
ium
chl
orid
e 1 .
5gm
B .P .
, so
dium
chl
orid
e 2 .
6gm
B .P .
93so
dium
pho
spha
te
enem
a7 .
2g /1
20m
l
ESSENTIAL MEDICINES LIST | 63 62 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
94
bisa
cody
lta
blet
5mg
95
glyc
erin
supp
osito
ry
96m
agne
sium
oxi
des
and
hydr
oxid
essu
spen
sion
7 .9%
w/v
QC
ardi
ovas
cula
r m
edic
ines
97ac
etyl
salic
ylic
aci
dta
blet
100m
g
98bi
sopr
ololª
tabl
et1 .
25m
g; 5m
g
99di
goxi
nta
blet
62 .5
mcg
, 250
mcg
inje
ctio
n25
0mcg
/ml i
n 2m
l
100
dopa
min
e (h
ydro
chlo
ride
)in
ject
ion
40m
g/m
l in
5ml v
ial
101
enal
apri
l (m
alea
te)ª
tabl
et2 .
5mg,
5mg
102
glyc
eryl
tri
nitr
ate
subl
ingu
al50
0 m
cg
For
seve
re P
IH o
nly
103
hydr
alaz
ine
(hyd
roch
lori
de)
inje
ctio
n20
mg
tabl
et25
mg,
50m
g
104
isos
orbi
de d
initr
ateª
su
blin
gual
5mg
For
seve
re P
IH o
nly
105
met
hyld
opa
tabl
et25
0mg,
500m
g
inje
ctio
n25
0mg
106
prop
rano
lol (
HC
l)ta
blet
/cap
s10
mg,
40m
g, 80
mg
107
sim
vast
atinª
tabl
et5m
g, 10
mg,
20m
g, 40
mg
108
vera
pam
il (h
ydro
chlo
ride
)ta
blet
40m
g, 80
mg
R
Diu
retic
s
109
furo
sem
ideª
tabl
et20
mg,
40m
g
inje
ctio
n10
mg
110
hydr
ochl
orot
hiaz
ideª
tabl
et12
.5m
g, 25
mg
111
spir
onol
acto
neta
blet
25m
g
SM
edic
ines
affe
ctin
g co
agul
atio
n11
2he
pari
n so
dium
inje
ctio
n1,
000,
5,0
00, 2
0,00
0 IU
/ml
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
11
3tr
anex
amic
aci
din
ject
ion
100m
g/m
l in
10m
l
caps
ule
250m
g, 50
0mg
114
war
fari
n (s
odiu
m)ª
tabl
et1m
g, 2m
g, 5m
g
TA
ntiv
iral
s fo
r he
patit
is
115
inte
rfer
on a
lpha
2b
inje
ctio
n3
MIU
116
riba
viri
neta
blet
200m
g, 40
0mg,
600m
g
UA
nti-H
erpe
s m
edic
ines
117
acyc
lovi
rª
tabl
et20
0mg
syru
p20
0mg/
5ml
crea
m/o
intm
ent
5% w
/w
VO
xyto
cic
med
icin
es11
8er
gom
etri
ne
(hyd
roge
n m
alea
te)ª
inje
ctio
n20
0mcg
in 1
ml
119
mis
opro
stol
tabl
et20
0mcg
120
oxyt
ocin
inje
ctio
n10
IU in
1m
l
W
Res
pira
tory
med
icin
es
121
amin
ophy
lline
in
ject
ion
25m
g/m
l in
10m
l
tabl
et10
0mg
122
becl
omet
haso
ne
(dip
ropi
onat
e)In
hala
tion
(aer
osol
)50
mcg
per
dos
e
123
salb
utam
ol (
sulfa
te)ª
tabl
et2m
g, 4m
g
Inha
latio
n (a
eros
ol)
100m
cg p
er d
ose
solu
tion
for
nebu
lizer
5mg
/ml
inje
ctio
n50
mcg
in 5
ml
124
amm
oniu
m c
hlor
ide
+
chlo
rofo
rm +
men
thol
+
diph
enhy
dram
ine
+ s
odiu
m
citr
ate
antit
ussi
ve e
xpec
tora
nt13
1 .5m
g/5m
l + 2
2mg/
5ml +
1m
g/5m
l + 1
3 .5m
g/5m
l + 5
5mg/
5ml
125
dext
rom
etho
rpha
n +
di
phen
hydr
amin
ean
titus
sive
syr
up12
.5m
g/5m
l + 1
2 .5m
g/5m
l
ESSENTIAL MEDICINES LIST | 65 64 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
XO
phth
alm
ic
126
dexa
met
haso
neey
e dr
ops
0 .1%
w/v
127
gent
amic
in (
sulfa
te)ª
eye
drop
s0 .
30%
128
trop
icam
ide
eye
drop
s1%
w/v
129
pilo
carp
ine
(h
ydro
chlo
ride
or
nitr
ate)
eye
drop
s2%
; 4%
130
tetr
acyc
line
(hyd
roch
lori
de)ª
eye
oint
men
t1%
eye
drop
s0 .
50%
131
poly
myx
in B
(su
lpha
te)
+
baci
trac
in z
inc
eye
oint
men
t10
,000
IU/g
+ 5
00 IU
/g
132
tetr
acai
ne (
hydr
ochl
orid
e)
ò ª
drop
s0 .
50%
133
timol
ol (
hydr
ogen
mal
eate
)ªey
e dr
ops
0 .25
%; 0
.5%
YEN
T
134
boro
glyc
erin
eea
r dr
ops
(onl
y fo
r w
ax
rem
ovin
g)40
%
135
poly
myx
in B
sul
phat
e +
lig
noca
ine
ear
drop
s
each
ml c
onta
ins
poly
myx
in
B (s
ulph
ate)
:100
0IU
/m
l,lig
noca
ine:
50m
g/m
l]; 5
ml p
last
ic
bott
le
136
cipr
oflox
acin
ear
drop
s0 .
30%
137
ephe
drin
e na
sal d
rops
0 .5%
138
ligno
cain
eto
pica
l sol
utio
n4%
139
salin
e na
sal d
rops
nasa
l dro
ps0 .
9%
140
xylo
met
azol
ineò
ªna
sal s
pray
0 .05
%
ZA
nti-L
eish
man
iasi
s
med
icin
es14
1am
phot
eric
in B
inje
ctio
n50
mg
in v
ial
142
sodi
um s
tibog
luco
nate
inje
ctio
n10
0mg/
ml i
n 30
ml v
ial
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
AA
I/V
infu
sion
s Pl
asm
a su
bstit
utes
143
plas
ma
expa
nder
infu
sion
dext
ran
6% w
/v,
gluc
ose
5% w
/v
144
gluc
ose/
dext
rose
infu
sion
5, 1
0%
ampu
le25
%
145
norm
al s
alin
ein
fusi
on0 .
9%
146
dext
rose
+ s
alin
ein
fusi
on5%
, 10%
147
Rin
ger’s
lact
ateª
infu
sion
infu
sion
,1,0
00m
l con
tain
s ca
lciu
m
chlo
ride
0 .2
gm U
.S .P .
; pot
assi
um
chlo
ride
0 .3
gm U
.S .P .
; sod
ium
ch
lori
de 6
gm U
.S .P .
; sod
ium
lact
ate
3 .1g
m U
.S .P .
; ste
rile
wat
er fo
r in
ject
ion
1,00
0ml (
q .s .
);1,0
00m
l co
llaps
ible
pla
stic
bot
tle
147
pota
ssiu
m c
hlor
ide
solu
tion
11 .2
% in
20m
l am
poul
e
148
sodi
um b
icar
bona
tein
ject
ion
1 .4%
isot
onic
149
man
nito
lin
fusi
on10
% a
nd 2
0% w
/v (
500m
l)
150
wat
er fo
r in
ject
ion
ampu
le5m
l, 10
ml
AB
D
erm
atol
ogic
als
151
benz
yl b
enzo
ateò
ª
lotio
n5%
, 25%
152
beta
met
haso
neò
ªcr
eam
/oin
tmen
t0 .
1%
153
cala
min
eªlo
tion
15%
154
coal
tar
lotio
n5%
155
clot
rim
azol
eto
pica
l cre
am1%
w/w
156
hydr
ocor
tison
eªcr
eam
1%
157
perm
ethr
incr
eam
/lotio
n5%
/1%
158
salic
ylic
aci
dso
lutio
n5%
ESSENTIAL MEDICINES LIST | 67 66 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
15
9po
lym
yxin
B (
sulp
hate
) +
ba
citr
acin
zin
coi
ntm
ent
10,0
00 IU
/g +
500
IU
/g
160
silv
er s
ulph
adia
zineò
crea
m1%
161
sodi
um t
hios
ulph
ate
solu
tion
15%
AC
Vita
min
s an
d m
iner
als
162
asco
rbic
aci
dta
blet
50m
g, 10
0mg,
500m
g
163
calc
ium
glu
cona
tein
ject
ion
100m
g/m
l in
10m
l
164
calc
ium
lact
ate
tabl
et50
0mg,
1gm
165
ergo
calc
ifero
l (vi
tam
in D
)ªta
blet
1 .25
mg
(50,
000
IU)
166
ferr
ous
salt
(fum
erat
e)ta
blet
equi
vale
nt t
o 60
mg
iron
syru
peq
uiva
lent
to
25m
g/m
l iro
n
167
folic
aci
d ta
blet
0 .5m
g, 1m
g, an
d 5m
g
168
ferr
ous
salt
+ fo
lic a
cid
tabl
et (
DR
AP
appr
oved
)ta
blet
, equ
ival
ent
to 6
0mg
iron
+
400
mcg
folic
aci
d
169
vita
min
Kin
ject
ion
10m
g
170
hydr
oxoc
obal
amin
ampu
le1m
g in
1m
l
171
mul
tiple
mic
ronu
trie
nts
sach
et
172
retin
ol (
vita
min
A)
tabl
et/ c
apsu
le50
,000
IU; 1
00,0
00 IU
; 200
,000
IU
(as
palm
itate
)
For
acut
e di
arrh
ea
173
zinc
sul
phat
edi
sper
sibl
e ta
blet
20m
g
174
B co
mpl
ex (
B1, B
6, a
nd B
12)
tabl
et
175
mul
tivita
min
sta
blet
AD
Con
trac
eptiv
es17
6co
ndom
s
177
ethy
nyle
stra
diolª
+
nore
this
tero
neª
co
mbi
ned
oral
pill
s35
mcg
+ 1
mg
178
levo
norg
estr
elª
pr
oges
tero
n on
ly p
ills
30m
cg
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
17
9le
vono
rges
trel
em
erge
ncy
cont
race
ptiv
e pi
lls75
0 m
cg (
pack
of 2
)
180
copp
er T
/mul
tiloa
dIU
CD
181
DM
PA (
med
roxy
prog
este
rone
ac
etat
e)in
ject
ion
150m
g /1
ml
182
nore
this
tero
ne e
nant
ate
inje
ctio
n20
0mg/
ml i
n 1m
l
183
estr
adio
l cyp
iona
te +
m
edro
xypr
oges
tero
ne a
ceta
tein
ject
ion
5mg
+ 2
5mg
184
levo
norg
estr
el-r
elea
sing
im
plan
tsu
bder
mal
impl
ant
2 ro
d 75
mg
each
(us
e lif
e: 5
yea
rs)
185
eton
oges
trel
-rel
easi
ng im
plan
tsu
bder
mal
impl
ant
1 ro
d 68
mg
each
(us
e lif
e: 3
yea
rs)
AE
Va
ccin
es a
nd s
era
186
BCG
vac
cine
WH
O a
ppro
ved/
as p
er
natio
nal E
PI p
rogr
am
187
DPT
vac
cine
188
polio
vac
cine
(O
PV t
riva
lant
)/IP
Vor
al/ i
njec
tion
189
hepa
titis
vac
cine
190
mea
sles
vac
cine
191
teta
nus
toxo
id
192
pent
aval
ant
vacc
ine
193
pneu
moc
occa
l vac
cine
194
men
ingo
cocc
al v
acci
ne
195
anti-
rabi
es v
acci
ne (
PRV
R)
sing
le d
ose
vial
>2 .
5 IU
196
anti-
snak
e ve
nom
ser
um
197
anti
D im
mun
oglo
bulin
(h
uman
)si
ngle
dos
e vi
al25
0mg
198
diph
ther
ia a
ntito
xin
vial
10,0
00 IU
; 20,
000
IU
ESSENTIAL MEDICINES LIST | 69 68 | ESSENTIAL MEDICINES LIST
EML FOR THQsEML FOR THQs
TH
Qs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
199
teta
nus
imm
unog
lobu
lin
(hum
an)
inje
ctio
n50
0 IU
in v
ial
200
rabi
es im
mun
oglo
bulin
(h
uman
)vi
al15
0 IU
/ml
AF
M
edic
ines
for
men
tal a
nd
beha
vior
al d
isor
ders
201
chlo
rpro
maz
ine
(hyd
roch
lori
de)ª
inje
ctio
n25
mg
in 2
ml
tabl
et10
0mg
202
halo
peri
dol
tabl
et5m
g
203
alpr
azol
amta
blet
0 .5m
g
Tran
quili
zers
204
diaz
epam
tabl
et2m
g, 5m
g
inje
ctio
n10
mg
Ant
i-Mig
rain
e 20
5m
igri
lta
blet
206
caaf
ergo
tta
blet
AG
A
ntis
eptic
s/
disi
nfec
tant
s20
7po
vido
ne-io
dine
solu
tion
10%
w/v
Onl
y ch
lorin
e-ba
sed
com
poun
d in
sta
ble
dry
gran
ular
form
250
halo
gena
ted
natr
ium
ph
osph
ate
pow
der
100g
m
208
chlo
rhex
idin
e +
cet
erim
ide
solu
tion
1 .5%
w/v
+ 1
5% w
/v
209
acri
flavi
necr
eam
0 .1%
w/w
210
tinct
ure
benz
oin
Co
Solu
tion
7 .5%
w/v
Antis
eptic
s fo
r co
rd c
are
211
chlo
rhex
idin
e di
gluc
onat
e (7
.1%
) fo
r co
rd c
are
solu
tion,
gel
equi
vale
nt t
o 4%
chl
orhe
xidi
ne
AH
Dis
posa
ble
supp
lies
212
syri
nge
(aut
odis
able
)st
erile
pac
ks1c
c, 5c
c
213
disp
osab
le s
yrin
gest
erile
pac
ks50
cc
214
IV s
ets
(DR
AP
appr
oved
)st
erile
pac
ks
215
scal
p ve
in s
et (
DR
AP
appr
oved
)st
erile
pac
ks
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
216
volu
met
ric
cham
ber
(IV
bure
tte)
ster
ile p
acks
100m
l siz
e
217
IV c
anul
a (D
RA
P ap
prov
ed)
ster
ile p
acks
16G
, 20G
, 24G
218
adhe
sive
tap
e (h
ypoa
llerg
enic
)ro
ll1
inch
, 2 in
ch
219
ster
ile g
auze
dre
ssin
g7 .
5 x
7 .5
cm (
10 p
ly)
220
cott
on b
anda
gero
ll6 .
5cm
x 2
m
221
abso
rben
t co
tton
woo
lpa
ck50
0gm
222
crep
e ba
ndag
ero
ll7 .
5, 1
0cm
x 2
.7m
223
exam
inat
ion
glov
espa
irs
box
of 1
00 (
smal
l, m
ediu
m a
nd la
rge
size
) [1
:2:1
]
224
ster
ile s
urgi
cal g
love
spa
irs
6, 6
½, 7
, 7½
, 8
225
silk
sut
ures
ste
rile
12/p
ack
0, 1
/0, 2
/0, 3
/0, 4
/0
226
chro
mic
cat
gut
ster
ilest
erile
pac
ks0,
1/0
, 2/0
, 3/0
, 4/0
227
silk
sut
ures
ste
rile
12/p
ack
8/0,
10/
0
228
prol
ene/
vicr
yl s
teri
le s
utur
esst
erile
pac
ks0,
1/0
, 2/0
, 3/0
, 4/0
229
plas
ter
of p
aris
ban
dage
roll
10cm
, 20c
m x
6m
230
face
mas
ks d
ispo
sabl
e
231
bloo
d la
ncet
sst
erile
pac
ks
232
slid
esst
erile
pac
ks
233
endo
trac
heal
tub
est
erile
pac
ksse
t of
12
234
naso
gast
ric
tube
ster
ile p
acks
adul
t/pa
ds
235
Fole
y ca
thet
erst
erile
pac
ksal
l siz
es
236
urin
e ba
gsst
erile
pac
ks
237
bloo
d ba
gsst
erile
pac
ks
238
disp
osab
le a
irw
ays
ster
ile p
acks
all s
izes
ESSENTIAL MEDICINES LIST | 71 70 | ESSENTIAL MEDICINES LIST
EML FOR THQs
TH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
239
suct
ion
cath
eter
ster
ile p
acks
240
disp
osab
le c
ord
clam
psst
erile
pac
ks
241
spin
al n
eedl
est
erile
pac
ks
242
surg
ical
bla
des
ster
ile p
acks
cl
ean
deliv
ery
kits
ster
ile p
acks
• 1
bath
soa
p, 5
0 gr
am w
rapp
ed
• 1
apro
n
• 2
pap
er t
owel
• 2
pai
rs o
f lat
ex e
xam
inat
ion
glov
es (
M)
• 1
plas
tic u
nder
shee
t (a
bout
one
sq
uare
met
er)
• 1
unde
rpad
60
cm x
90
cm
• 2
alc
ohol
pad
s
• 2
pac
ks o
f spo
nges
(4
spon
ges)
• 1
ster
ile b
ulb
suck
er
• 2
ste
rile
um
bilic
al c
ord
clam
p
• 1
ster
ile s
urgi
cal b
lade
• 2
cot
ton
thre
ad (
cord
tie
s)
• 1
mat
erni
ty p
ad
• 1
whi
te p
oly
bag
for
disp
osal
• 1
unbl
each
ed d
igni
ty d
rape
• 1
inst
ruct
ion
shee
t
AI
Rad
ioco
ntra
st m
edia
24
3am
idot
rizo
ate
inje
ctio
n14
0mg
to 4
20m
g
iodi
ne/m
l in
20m
l
244
bari
um s
ulfa
teaq
ueou
s su
spen
sion
245
Iohe
xol
inje
ctio
n14
0mg
to 3
50m
g io
dine
/ml
in 5
ml;
10m
l; 20
ml a
mpo
ules
EML FOR DHQs
ª Primarily indicates similar clinical performance within a pharmacological class.
ò Indicates that the medicine has an age or weight restriction.
© Signifies a specific indication for restricting its use for children.
ESSENTIAL MEDICINES LIST | 73
EML FOR DHQs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
A
Ane
sthe
tics
gene
ral
1ha
loth
ane/
isofl
uran
ein
hala
tion
2ni
trou
s ox
ide
inha
latio
n
3ox
ygen
(m
edic
inal
gas
) cy
linde
rin
hala
tion
4ke
tam
ine
(hyd
roch
lori
de)
inje
ctio
n50
mg/
ml i
n 10
ml
5th
iope
ntal
(so
dium
)in
ject
ion
10m
g/m
l, 20
mg/
ml
B
Mus
cle
rela
xant
s6
atra
curi
um (
besy
late
)ªin
ject
ion
10m
g/m
l
7ne
ostig
min
e (m
etils
ulfa
te)
inje
ctio
n2 .
5mg
in 1
ml
(bro
mid
e)ta
blet
15m
g
8su
xam
etho
nium
(ch
lori
de)
ampo
ule
50m
g/m
l in
2ml
C
Ane
sthe
tics
loca
l9
bupi
vaca
ine
(hyd
roch
lori
de)ª
vial
0 .25
%, 0
.5%
inje
ctio
n fo
r sp
inal
ane
sthe
sia
ampo
ule
(5m
g/m
l) 0 .
5% in
4m
l
10lid
ocai
ne (
hydr
ochl
orid
e)ª
vial
5% (
hydr
ochl
orid
e) in
2m
l am
poul
e to
be
mix
ed w
ith 7
.5%
glu
cose
so
lutio
n .
topi
cal f
orm
s2%
gel
, 4%
sol
utio
n
11lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
inje
ctio
n2%
+ 1
:200
,000
12lig
noca
ine
+ e
pine
phri
ne
(adr
enal
ine)
dent
al c
artr
idge
2% +
1:8
0,00
0
13ep
hedr
ine
(hyd
roch
lori
de)
ampo
ule
30m
g in
1m
l
D
Ana
lges
ics
O
pioi
d/ce
ntra
l act
ing
14m
orph
ine
(sul
phat
e or
hy
droc
hlor
ide)
ampo
ule
10m
g/1m
l
15pe
thid
ine
(hyd
roch
lori
de)
ampu
le50
mg/
ml i
n 2m
l
nalb
uphi
ne (
HC
l)in
ject
ion
10m
g/m
l, 20
mg/
ml
ESSENTIAL MEDICINES LIST | 75 74 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
16m
idaz
olam
inje
ctio
n1m
g/m
l
tabl
et7 .
5mg
EA
nalg
esic
s/N
SAID
s17
acet
ylsa
licyl
ic a
cid
disp
ersi
ble
tabl
et30
0mg
supp
osito
ry50
mg
to 1
50m
g
18di
clof
enac
(so
dium
)
tabl
et50
mg
ampu
le75
mg
in 3
ml
gel
3% w
/w
19na
prox
enta
blet
250m
g, 50
0mg
20m
elox
icam
tabl
et7 .
5mg,
15m
g
21ib
upro
fenò
tabl
et20
0mg,
400m
g
gel
10%
w/w
syru
p20
0mg/
5ml
22pa
race
tam
ol
tabl
et50
0mg
syru
p12
5mg/
5ml
inje
ctio
n15
0mg/
ml
supp
osito
ry10
0mg
FM
edic
ines
to
trea
t go
ut23
allo
puri
nol
tabl
et10
0mg
GA
nti-A
llerg
ics
and
med
icin
es u
sed
in
anap
hyla
xis
24ch
lorp
heni
ram
ine
(hyd
roge
n
mal
eate
)ò ª
tabl
et4m
g
inje
ctio
n10
mg/
ml
syru
p©2m
g/5m
l
25ce
tiriz
ine
tabl
et10
mg
syru
p5m
g/5m
l
26lo
rata
dine
tabl
et10
mg
syru
p1m
g/m
l
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
27pr
omet
hazi
ne (
HC
l)
tabl
et25
mg
syru
p25
mg/
5ml
inje
ctio
n25
mg/
ml i
n 2m
l
28de
xam
etha
sone
(d
isod
ium
pho
spha
te)
inje
ctio
n4m
g/m
l
tabl
et0 .
5mg
29ep
inep
hrin
e (a
dren
alin
e)am
pule
1mg
/ml
30hy
droc
ortis
one
(sod
ium
su
ccin
ate)
inje
ctio
n10
0mg,
250m
g
31pr
edni
solo
neª
tabl
et5m
g
H
AN
TI-I
NFE
CT
IVES
A
ntib
iotic
s/ a
ntim
icro
bial
32
amox
icill
in (
trih
ydra
te)
caps
ule/
tab
let
250m
g, 50
0mg
(pre
fera
bly
disp
ersi
ble
tabl
et)
pow
der
for
susp
ensi
on©
125m
g, 25
0mg
/5m
l
inje
ctio
n25
0mg,
500m
g
33am
pici
llin
(sod
ium
)
caps
ule
250m
g, 50
0mg
pow
der
for
susp
ensi
on©
125m
g, 25
0mg/
5ml
inje
ctio
n50
0mg
and
1g
Rese
rved
2nd
line
34
amik
acin
(su
lfate
)in
ject
ion
500m
g, 1g
m
35az
ithro
myc
inª
caps
ule
250m
g, 50
0mg
susp
ensi
on12
5mg/
5ml i
n 22
.5m
l
36am
oxic
illin
+ c
lavu
lani
c ac
idta
blet
375m
g
inje
ctio
n1g
m
37be
nzat
hine
pen
icill
inin
ject
ion©
0 .6m
IU, 1
.2 m
IU
38cl
oxac
illin
caps
ule
250m
g, 50
0mg
pow
der
for
susp
ensi
on©
125m
g, 25
0mg/
5ml
ESSENTIAL MEDICINES LIST | 77 76 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
Onl
y lis
ted
for
sing
le-
dose
tre
atm
ent
of
unco
mpl
icat
ed a
no-
geni
tal g
onor
rhea
39ce
fixim
e* (
trih
ydra
te)
caps
ule
400m
g
syru
p10
0mg,
200m
g/5m
l
40ce
ftri
axon
e (s
odiu
m)ò
pow
der
for
inje
ctio
n25
0mg,
500m
g, 1g
m
Onl
y fo
r ep
idem
ic m
enin
gitis
41
chlo
ram
phen
icol
ca
psul
e25
0mg
(pal
mita
te)
syru
p12
5mg/
5ml
(sod
ium
suc
cina
te)
inje
ctio
n1g
m
42ci
profl
oxac
in (h
ydro
chlo
ride
)ªta
blet
250m
g, 50
0mg
infu
sion
500m
g/10
0ml
Reco
mm
ende
d fo
r us
e in
co
mbi
natio
n re
gim
ens
for
erad
icatio
n of
H. p
ylori
in
adul
ts
43cl
arith
rom
ycin
*ta
blet
500m
g
44cl
inda
myc
in (
hydr
ochl
orid
e)
(pho
spha
te)
caps
ule
150m
g, 30
0mg
inje
ctio
n15
0mg/
ml
45co
trim
oxaz
oleò
(s
ulfa
met
hoxa
zole
+
rim
etho
prim
)
tabl
et©
400m
g +
80m
g
syru
p©20
0mg
+ 4
0mg/
5ml
46do
xycy
clin
e (h
ycla
te)ò
caps
ule©
100m
g
syru
p©25
mg/
5ml
47flu
clox
acill
in
[flox
acill
in s
odiu
m]
inje
ctio
n25
0mg,
500m
g
caps
ule
250m
g, 50
0mg
48ge
ntam
icin
(su
lfate
)ªin
ject
ion
40m
g, 80
mg
for
mul
tidru
g-re
sista
nce
(MD
R) tu
berc
ulos
is (T
B)49
kana
myc
in (
sulfa
te)
inje
ctio
n50
0mg,
1gm
50le
voflo
xaci
nta
blet
250m
g, 50
0mg
inje
ctio
n50
0mg
51m
etro
nida
zoleª
ta
blet
200m
g, 40
0mg
inje
ctio
n50
0mg
in 1
00m
l
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
(b
enzo
ate)
syru
p20
0mg/
5ml
52
nitr
ofur
anto
in
tabl
et10
0mg
53pr
ocai
ne b
enzy
lpen
icill
in
inje
ctio
n1m
IU, 3
m IU
54ph
enox
ymet
hylp
enic
illin
(p
otas
sium
)ta
blet
250m
g, 50
0mg
syru
p12
5mg/
5ml
55va
ncom
ycin
(H
Cl)
inje
ctio
n50
0mg
I A
ntid
otes
and
oth
er
subs
tanc
es u
sed
in
pois
onin
gs
56at
ropi
ne (
sulfa
te)ò
ampu
le1m
g in
1m
l
57ch
arco
al a
ctiv
ated
pow
der
58m
ethy
lthio
nini
um c
hlor
ide
(met
hyle
ne b
lue)
ampu
le10
mg/
ml i
n 10
ml
59na
loxo
ne (
hydr
ochl
orid
e)am
pule
400
mcg
in 1
ml
J A
nti-E
pile
ptic
s A
ntic
onvu
lsan
ts
For
ecle
mps
ia o
nly
60ca
rbam
azep
ine
tabl
et20
0mg
syru
p10
0mg/
5ml
61m
agne
sium
sul
phat
ein
ject
ion
500m
g/m
l
62ph
enob
arbi
tal (
sodi
um)
tabl
et30
mg
inje
ctio
n20
0mg
/ml
63va
lpro
ic a
cid
(sod
ium
va
lpro
ate)
inje
ctio
n20
0mg/
5ml
tabl
et20
0mg,
500m
g
64ph
enyt
oin
(sod
ium
)ta
blet
100m
g
syru
p30
mg/
5ml
K
Ant
i-Hel
min
thic
65al
bend
azol
e ta
blet
200m
g
syru
p10
0mg/
5ml
66m
eben
dazo
le (
chew
able
)ta
blet
500m
g (w
ith c
autio
n—on
ly fo
r ad
ults
)
67py
rant
el (
pam
oate
)ta
blet
250m
g
syru
p25
0mg/
5ml
ESSENTIAL MEDICINES LIST | 79 78 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
LA
nti-F
unga
l68
clot
rim
azol
eva
gina
l cre
am1%
w/v
vagi
nal t
able
t10
0mg,
500m
g
69flu
cona
zoleª
caps
ule
50m
g
inje
ctio
n2m
g/m
l
syru
p50
mg/
5ml
70ny
stat
in
tabl
et50
0,00
0 IU
drop
s©10
0,00
0 IU
/ml
pess
ary
100,
000
IU
M
Ant
i-Tub
ercu
losi
s dr
ugs
As
per T
B co
ntro
l pr
ogra
m g
uide
lines
71et
ham
buto
lta
blet
400m
g
oral
liqu
id©
25m
g/m
l
72is
onia
zid
tabl
et/s
yrup
©50
mg,
100m
g, 30
0mg
73py
razi
nam
ide
tabl
et50
0mg
74ri
fam
pici
nca
psul
es/s
yrup
©15
0mg,
300m
g, 45
0mg,
600m
g
75st
rept
omyc
inin
ject
ion
1gm
76et
ham
buto
l + is
onia
zid
tabl
et40
0mg
+ 1
50m
g
77is
onia
zid
+ r
ifam
pici
nta
blet
75m
g +
150
mg;
150m
g +
300
mg
78is
onia
zid
+ p
yraz
inam
ide
+
rifa
mpi
cin
tabl
et75
mg
+ 4
00m
g +
150
mg
79ri
fam
pici
n +
ison
iazi
d +
ta
blet
80et
ham
buto
l + is
onia
zid
+
rifa
mpi
cin
tabl
et27
5mg
+ 7
5mg
+ 1
50m
g
NA
nti-H
erpe
s m
edic
ines
81ac
iclo
virª
tabl
et20
0mg
OA
nti-L
eish
man
iasi
s
med
icin
es82
amph
oter
icin
bin
ject
ion
50m
g in
via
l
83so
dium
stib
oglu
cona
tein
ject
ion
100m
g/m
l in
30m
l via
l
PA
nti-D
iabe
tics
84gl
iben
clam
ide
tabl
et5m
g
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
85gl
imep
irid
e ta
blet
1mg,
2mg,
3mg
86m
etfo
rmin
(hy
droc
hlor
ide)
tabl
et50
0mg
87in
sulin
reg
ular
inje
ctio
n10
0 IU
/ml
88in
sulin
com
pin
ject
ion
30%
+ 7
0% w
/v
Q
Ant
imal
aria
l89
chlo
roqu
ine
(pho
spha
te o
r su
lfate
)ta
blet
150m
g
syru
p50
mg/
5ml
90qu
inin
eta
blet
300m
g
inje
ctio
n30
0mg/
ml
For
vivax
91pr
imaq
uine
(di
phos
phat
e)ta
blet
15m
g
For
falci
paru
m92
sulp
hado
xine
+ p
yrim
etha
min
eta
blet
500m
g +
25m
g
To b
e us
ed in
com
bina
tion
(co-
blist
er)
93
arte
suna
te +
sul
phad
oxin
e +
py
rim
etha
min
eta
blet
co-b
liste
r of
(6
+ 2
) ta
blet
—tw
o la
rge
tabl
ets,
each
has
sul
fado
xine
50
0mg
U .S
.P . +
pyr
imet
ham
ine
25m
g U
.S .P
—si
x sm
all t
able
ts ,e
ach
cont
ains
art
esun
ate
50m
g U
.S .P .
arte
suna
te +
sul
phad
oxin
e an
d py
rim
etha
min
eta
blet
co-b
liste
r of
(6
+ 3
) ta
blet
—3
larg
e ta
blet
s, ea
ch h
as s
ulfa
doxi
ne
500m
g U
.S .P .
+ p
yrim
etha
min
e 25
mg
U .S
.P .—
6 sm
all t
able
ts, e
ach
tabl
et
cont
ains
art
esun
ate
100m
g U
.S .P .
Man
agem
ent o
f sev
ere
mal
aria
94
arte
met
her*
ampu
le80
mg/
ml i
n 1m
l
95ar
tem
ethe
r +
lum
efan
trin
e*ta
blet
©20
mg
+ 1
20m
g
R
GIT
med
icin
es96
hyos
cine
(bu
tylb
rom
ide)
inje
ctio
n20
mg/
ml
tabl
et10
mg
97ph
loro
gluc
inol
tabl
etph
loro
gluc
inol
80m
g +
tr
imet
hylp
hlor
oglu
cino
l 80m
g
ESSENTIAL MEDICINES LIST | 81 80 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
98
met
oclo
pram
ide
(hyd
roch
lori
de)ò
tabl
ets
10m
g
syru
p5m
g/5m
l
inje
ctio
n5m
g/m
l
99om
epra
zoleª
caps
ules
10m
g, 20
mg,
40m
g
100
rani
tidin
ein
ject
ion
25m
g/m
l in
2ml
tabl
ets
150m
g, 25
0mg
101
alum
iniu
m h
ydro
xide
+
mag
nesi
um t
risi
licat
eta
blet
s25
0mg
+ 5
00m
g
Reco
mm
ende
d in
co
mbi
natio
n w
ith z
inc
sulp
hate
20m
g di
sper
sible
ta
blet
in c
ase
of a
cute
di
arrh
ea10
2O
RS
(low
osm
olar
ity)
sach
et
Dry
mix
ture
(lo
w o
smol
arity
fo
rmul
a) in
sac
het
for
1 lit
er o
f so
lutio
n, e
ach
sach
et c
onta
ins
gluc
ose
anhy
drou
s 13
.5gm
B .P .
, tr
isod
ium
citr
ate
dihy
drat
e 2 .
9gm
B .
P ., p
otas
sium
chl
orid
e1 .5
gm B
.P .,
sodi
um c
hlor
ide
2 .6g
m B
.P .
103
sodi
um p
hosp
hate
en
ema
7 .2g
/120
ml
104
lact
ulos
esy
rup
3 .35
g/5m
l in
120m
l
105
bisa
cody
lta
blet
5mg
106
glyc
erin
supp
osito
ry
107
mag
nesi
um o
xide
and
hy
drox
ide
susp
ensi
on7 .
9% w
/v
S
Ant
ivir
als
for
hepa
titis
108
inte
rfer
on a
lpha
2b
inje
ctio
n3
mill
ion
inte
rnat
iona
l uni
ts (
MIU
)
109
riba
viri
neta
blet
200m
g, 40
0mg,
600m
g
110
lam
ivud
ine
tabl
et15
0mg
T
Car
diov
ascu
lar
med
icin
es11
1ac
etyl
salic
ylic
aci
dta
blet
100m
g
112
biso
prol
olª
tabl
et1 .
25m
g, 5m
g
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
11
3di
goxi
nta
blet
62 .5
mcg
, 250
mcg
inje
ctio
n25
0mcg
/ml i
n 2m
l
114
dopa
min
e (h
ydro
chlo
ride
)in
ject
ion
40m
g/m
l in
5ml v
ial
115
dobu
tam
ine
(hyd
roch
lori
de)
inje
ctio
n50
mg/
ml i
n 5m
l
116
enal
apri
l (m
alea
te)ª
tabl
et2 .
5mg,
5mg
117
glyc
eryl
tri
nitr
ate
subl
ingu
al50
0 m
cg
For
seve
re P
IH o
nly
118
hydr
alaz
ine
(hyd
roch
lori
de)
inje
ctio
n20
mg
tabl
et25
mg,
50m
g
119
isos
orbi
de d
initr
ateª
su
blin
gual
5mg
For
seve
re P
IH o
nly
120
met
hyld
opa
tabl
et25
0mg,
500m
g
inje
ctio
n25
0mg
121
losa
rtan
ta
blet
25m
g, 50
mg,
100m
g
122
prop
rano
lol (
HC
l)ta
blet
/cap
s10
mg,
40m
g, 80
mg
123
stre
ptok
inas
epo
wde
r fo
r in
ject
ion
1 .5
mill
ion
IU
124
sim
vast
atinª
tabl
et5m
g, 10
mg,
20m
g, 40
mg
125
vera
pam
il (h
ydro
chlo
ride
)ta
blet
40m
g, 80
mg
UD
iure
tics
126
furo
sem
ideª
tabl
et20
mg,
40m
g
inje
ctio
n10
mg
127
hydr
ochl
orot
hiaz
ideª
tabl
et12
.5m
g, 25
mg
128
spir
onol
acto
neta
blet
25m
g
V
Med
icin
es a
ffect
ing
co
agul
atio
n12
9he
pari
n (s
odiu
m)
inje
ctio
n1,
000,
5,0
00, 2
0,00
0 IU
/ml
130
tran
exam
ic a
cid
inje
ctio
n10
0mg/
ml i
n 10
ml
caps
ule
250m
g, 50
0mg
131
clop
idog
rel
tabl
et75
mg,
150m
g, 30
0mg
132
war
fari
n (s
odiu
m)ª
tabl
et1m
g, 2m
g, 5m
g
ESSENTIAL MEDICINES LIST | 83 82 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
W
Oxy
toci
c m
edic
ines
133
ergo
met
rine
(h
ydro
gen
mal
eate
)ªin
ject
ion
200m
cg in
1m
l
134
mis
opro
stol
tabl
et20
0mcg
135
oxyt
ocin
inje
ctio
n10
IU in
1m
l
X
Res
pira
tory
med
icin
es
136
amin
ophy
lline
in
ject
ion
25m
g/m
l in
10m
l
tabl
et10
0mg
137
becl
omet
haso
ne
(dip
ropi
onat
e)in
hale
r50
mcg
per
dos
e
138
salb
utam
ol (
sulfa
te)ª
tabl
et2m
g, 4m
g
inha
ler
100m
cg p
er d
ose
solu
tion
for
nebu
lizer
5mg
/ml
inje
ctio
n50
mcg
in 5
ml
139
amm
oniu
m c
hlor
ide
+
chlo
rofo
rm +
men
thol
+
diph
enhy
dram
ine
+ s
odiu
m
citr
ate
antit
ussi
ve e
xpec
tora
nt13
1 .5m
g/5m
l + 2
2mg/
5ml +
1m
g/5m
l + 1
3 .5m
g/5m
l + 5
5mg/
5ml
140
dext
rom
etho
rpha
n +
di
phen
hydr
amin
ean
titus
sive
syr
up12
.5m
g/5m
l + 1
2 .5m
g/5m
l
Y
Oph
thal
mic
14
1de
xam
etha
sone
eye
drop
s0 .
1% w
/v
142
gent
amic
in (
sulfa
te)ª
eye
drop
s0 .
30%
143
trop
icam
ide
eye
drop
s1%
w/v
144
pilo
carp
ine
(hyd
roch
lori
de o
r ni
trat
e)ey
e dr
ops
2%, 4
%
145
cipr
oflox
acin
eye
drop
s
146
poly
myx
in B
(su
lpha
te)
+
baci
trac
in z
inc
eye
oint
men
t10
,000
IU/g
+ 5
00IU
/g
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
14
7te
trac
yclin
e (h
ydro
chlo
ride
)ªey
e oi
ntm
ent
1%
eye
drop
s0 .
50%
148
tetr
acai
ne (
hydr
ochl
orid
e)ò
ªdr
ops
0 .50
%
149
timol
ol (
hydr
ogen
mal
eate
)ªey
e dr
ops
0 .25
%, 0
.5%
Z
ENT
150
boro
glyc
erin
eea
r dr
ops
(onl
y fo
r w
ax
rem
ovin
g)40
%
151
poly
myx
in B
sul
phat
e +
lig
noca
ine
ear
drop
s
each
ml c
onta
ins
poly
myx
in
B (s
ulph
ate)
:100
0IU
/m
l,Lig
noca
ine:
50m
g/m
l]; 5
ml p
last
ic
bott
le
152
cipr
oflox
acin
ear
drop
s0 .
30%
153
ephe
drin
e na
sal d
rops
0 .5%
154
ligno
cain
eto
pica
l sol
utio
n4%
155
salin
e na
sal d
rops
nasa
l dro
ps0 .
9%
156
xylo
met
azol
ineò
ªna
sal s
pray
0 .05
%
AA
I/V
Infu
sion
s Pl
asm
a su
bstit
utes
157
plas
ma
expa
nder
infu
sion
dext
ran
6% w
/v, g
luco
se 5
% w
/v
158
gluc
ose/
dext
rose
infu
sion
5%, 1
0%
ampu
le25
%
159
norm
al s
alin
ein
fusi
on0 .
9%
160
dext
rose
+ s
alin
ein
fusi
on5%
+ 0
.9%
w/v
161
Rin
ger’s
lact
ateª
in
fusi
on
infu
sion
1,00
0ml c
onta
ins
calc
ium
ch
lori
de 0
.2gm
U .S
.P .; p
otas
sium
ch
lori
de 0
.3gm
U .S
.P .; s
odiu
m
chlo
ride
6gm
U .S
.P .; 3
.1gm
sod
ium
la
ctat
e U
.S .P .
, ste
rile
wat
er fo
r in
ject
ion
162
pota
ssiu
m c
hlor
ide
solu
tion
11 .2
% in
20m
l am
poul
e
ESSENTIAL MEDICINES LIST | 85 84 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
163
sodi
um b
icar
bona
tein
ject
ion
1 .4%
isot
onic
164
man
nito
lin
fusi
on20
% w
/v
165
wat
er fo
r in
ject
ion
ampu
le5m
l, 10
ml
AB
Vita
min
s an
d m
iner
als
166
asco
rbic
aci
dta
blet
50m
g, 10
0mg,
500m
g
167
calc
ium
glu
cona
tein
ject
ion
100m
g/m
l in
10m
l
168
calc
ium
lact
ate
tabl
et50
0mg,
1gm
169
ergo
calc
ifero
l (vi
tam
in D
)ªta
blet
1 .25
mg
(50,
000
IU)
170
ferr
ous
salt
tabl
eteq
uiva
lent
to
60m
g ir
on
syru
peq
uiva
lent
to
25m
g/m
l iro
n
171
folic
aci
d ta
blet
0 .5m
g,1m
g, 5m
g
172
ferr
ous
salt
+ fo
lic a
cid
tabl
etta
blet
, equ
ival
ent
to 6
0mg
iron
+
400m
cg fo
lic a
cid
173
vita
min
Kin
ject
ion
10m
g
174
hydr
oxoc
obal
amin
ampu
le1m
g in
1m
l
175
mul
tiple
mic
ronu
trie
nts
sach
et
176
retin
ol (
vita
min
A)
tabl
et/ c
apsu
le50
,000
IU; 1
00,0
00 IU
; 200
,000
IU
(as
palm
itate
)
Acut
e di
arrh
ea
177
zinc
sul
phat
edi
sper
sibl
e ta
blet
20m
g
178
B co
mpl
ex (
B1, B
6, a
nd B
12)
tabl
et
179
mul
tivita
min
sta
blet
AC
Der
mat
olog
ical
s18
0ª
ben
zyl b
enzo
ate ò
lo
tion
5%, 2
5%
181
ª b
etam
etha
sone
òcr
eam
/oin
tmen
t0 .
1%
182
ª c
alam
ine
lotio
n15
%
183
coal
tar
lotio
n5%
184
ª h
ydro
cort
ison
ecr
eam
1%
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
185
perm
ethr
incr
eam
/lotio
n5%
, 1%
186
salic
ylic
aci
dso
lutio
n5%
187
sele
nium
sul
fide
dete
rgen
t-ba
sed
susp
ensi
on2%
188
poly
myx
in B
(su
lpha
te)
+
baci
trac
in z
inc
oint
men
t10
,000
IU/g
+ 5
00 IU
/g
189
silv
er s
ulph
adia
zineò
crea
m1%
190
sodi
um t
hios
ulph
ate
solu
tion
15%
AD
M
edic
ines
for
men
tal a
nd
beha
vior
al d
isor
ders
Tr
anqu
ilize
rs
191
amitr
ipty
line
(hyd
roch
lori
de)
tabl
et25
mg
192
carb
amaz
epin
eta
blet
100m
g, 20
0mg
193
ª c
hlor
prom
azin
e (h
ydro
chlo
ride
)
inje
ctio
n25
mg
in 2
ml
tabl
et10
0mg
194
clom
ipra
min
e (h
ydro
chlo
ride
)ta
blet
10m
g, 25
mg
195
olan
zapi
neta
blet
5mg,
7mg,
5mg
196
risp
erid
one
tabl
et1m
g, 2m
g, 3m
g
197
fluox
etin
e (h
ydro
chlo
ride
) ò
©ta
blet
20m
g
198
ª fl
uphe
nazi
ne (
deca
noat
e or
en
anta
te)
tabl
et25
mg
199
diaz
epam
tabl
et2m
g, 5m
g
inje
ctio
n10
mg
200
alpr
azol
amta
blet
0 .5m
g
201
brom
azep
amta
blet
3mg
AE
C
ontr
acep
tives
202
cond
oms
203
ethy
nyle
stra
diolª
+
nore
this
tero
neª
CO
pill
s35
mcg
+ 1
mg
ESSENTIAL MEDICINES LIST | 87 86 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
204
levo
norg
estr
elª
PO p
ills
30m
cg
20
5le
vono
rges
trel
EC
pill
s75
0mcg
(pa
ck o
f 2)
206
copp
er T
/mul
tiloa
dIU
CD
207
med
roxy
prog
este
rone
ace
tate
(D
MPA
)in
ject
ion
150m
g/1m
l
208
nore
this
tero
ne e
nant
ate
inje
ctio
n20
0mg/
ml i
n 1m
l
209
estr
adio
l cyp
iona
te +
m
edro
xy-
prog
este
rone
ace
tate
m
edro
xypr
oges
tero
ne
acet
atem
edro
xypr
oges
tero
ne
acet
ate
inje
ctio
n5m
g +
25m
g
210
levo
norg
estr
el-r
elea
sing
im
plan
tsu
bder
mal
impl
ant
2 ro
d 75
mg
each
(us
e lif
e: 5
yea
rs)
211
eton
oges
trel
-rel
easi
ng im
plan
tsu
bder
mal
impl
ant
1 ro
d 68
mg
each
(us
e lif
e: 3
yea
rs)
AF
Va
ccin
es a
nd s
era
212
BCG
vac
cine
WH
O-a
ppro
ved/
as p
er
natio
nal E
PI p
rogr
am
213
DPT
vac
cine
214
polio
vac
cine
(O
PV t
riva
lent
)/ IP
Vor
al/ i
njec
tion
215
hepa
titis
vac
cine
216
mea
sles
vac
cine
217
teta
nus
toxo
id
218
pent
aval
ant
vacc
ine
219
pneu
moc
occa
l vac
cine
220
men
ingo
cocc
al v
acci
ne
221
anti-
rabi
es v
acci
ne (
PVRV
)si
ngle
-dos
e vi
al >
2 .5
IU
222
anti-
snak
e ve
nom
ser
um
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
223
anti-
D im
mun
oglo
bulin
(h
uman
)si
ngle
-dos
e vi
al25
0 m
icro
gram
s
224
diph
ther
ia a
ntito
xin
vial
10,0
00 IU
; 20
000
IU
225
teta
nus
imm
unog
lobu
lin
(hum
an)
inje
ctio
n50
0 IU
in v
ial
226
rabi
es im
mun
oglo
bulin
(h
uman
)vi
al15
0 IU
/ml
AG
Peri
tone
al d
ialy
sis
solu
tions
227
intr
aper
itone
al d
ialy
sis
solu
tion
pare
nter
al s
olut
ion
of a
ppro
pria
te c
ompo
sitio
n
AH
Im
mun
osup
pres
sive
s22
8az
athi
opri
ne
(as
sodi
um s
alt)
tabl
et50
mg
inje
ctio
n10
0mg
in v
ial
229
cicl
ospo
rin
caps
ule
25m
g
AI
Ant
i-Par
kins
on’s
230
bipe
ride
nin
ject
ion
5mg
(lact
ate)
in 1
ml
tabl
et2m
g (h
ydro
chlo
ride
)
231
levo
dopa
+ c
arbi
dopa
tabl
et10
0mg
+ 1
0mg;
250m
g +
25m
g
Thy
roid
/ ant
i-thy
roid
232
levo
thyr
oxin
eta
blet
50m
cg, 1
00 m
cg
233
prop
ylth
iour
acil
tabl
et50
mg
AJ
Ant
isep
tics
/dis
infe
ctan
ts23
4po
vido
ne-io
dine
solu
tion
10%
w/v
235
chlo
rhex
idin
e +
cet
erim
ide
solu
tion
1 .5%
w/v
+ 1
5% w
/v
Onl
y ch
lorin
e ba
sed
com
poun
d in
sta
ble
dry
gran
ular
form
236
halo
gena
ted
natr
ium
ph
osph
ate
pow
der
100g
ms
237
tinct
ure
benz
oin
com
poun
dso
lutio
n7 .
5% w
/v
Antis
eptic
s fo
r co
rd c
are
238
chlo
rhex
idin
e di
gluc
onat
e (7
.1%
) fo
r co
rd c
are
solu
tion,
gel
equi
vale
nt t
o 4%
chl
orhe
xidi
ne
AK
D
ispo
sabl
e su
pplie
s23
9sy
ring
e (a
utod
isab
le)
ster
ile p
acks
1cc,
5cc
240
disp
osab
le s
yrin
gest
erile
pac
ks50
cc
ESSENTIAL MEDICINES LIST | 89 88 | ESSENTIAL MEDICINES LIST
EML FOR DHQsEML FOR DHQs
DH
Qs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
241
IV s
ets
(DR
AP
appr
oved
)st
erile
pac
ks
242
scal
p ve
in s
et (
DR
AP
appr
oved
)st
erile
pac
ks
243
volu
met
ric
cham
ber
(IV
bure
tte)
ster
ile p
acks
100m
l
244
IV c
anul
a (D
RA
P ap
prov
ed)
ster
ile p
acks
16G
, 20G
, 24G
245
adhe
sive
tap
e (h
ypoa
llerg
enic
)ro
ll1
inch
, 2 in
ch
246
ster
ile g
auze
dre
ssin
g7 .
5 x
7 .5
cm (
10 p
ly)
247
cott
on b
anda
gero
ll6 .
5 cm
x 2
m
248
abso
rben
t co
tton
woo
lpa
ck50
0gm
249
crep
e ba
ndag
ero
ll7 .
5, 1
0 cm
x 2
.7m
250
exam
inat
ion
glov
espa
irbo
x of
100
(sm
all,
med
ium
, and
la
rge)
[1:
2:1]
251
ster
ile s
urgi
cal g
love
spa
ir6,
6½
, 7, 7
½, 8
251
silk
sut
ures
ste
rile
12/p
ack
0, 1
/0, 2
/0, 3
/0, 4
/0
252
chro
mic
cat
gut
ster
ilest
erile
pac
ks0,
1/0
, 2/0
, 3/0
, 4/0
253
silk
sut
ures
ste
rile
12/p
ack
8/0,
10/
0
254
prol
ene/
vicr
yl s
teri
le s
utur
esst
erile
pac
ks0,
1/0
, 2/0
, 3/0
, 4/0
255
plas
ter
of p
aris
ban
dage
roll
10 c
m, 2
0 cm
x 6
m
256
face
mas
ks d
ispo
sabl
e
257
bloo
d la
ncet
sst
erile
pac
ks
258
slid
esst
erile
pac
ks
259
endo
trac
heal
tub
est
erile
pac
ksSe
t of
12
260
naso
gast
ric
tube
ster
ile p
acks
adul
t/pa
ds
261
Fole
y ca
thet
erst
erile
pac
ksal
l siz
es
262
urin
e ba
gsst
erile
pac
ks
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
263
bloo
d ba
gsst
erile
pac
ks
264
disp
osab
le a
irw
ays
ster
ile p
acks
all s
izes
265
suct
ion
cath
eter
ster
ile p
acks
266
disp
osab
le c
ord
clam
psst
erile
pac
ks
267
spin
al n
eedl
est
erile
pac
ks
268
surg
ical
bla
des
ster
ile p
acks
269
clea
n de
liver
y ki
ts
ster
ile p
acks
• 1
bath
soa
p, 5
0 gr
am w
rapp
ed
• 1
apro
n
• 2
pap
er t
owel
• 2
pai
rs o
f lat
ex e
xam
inat
ion
glov
es (
M)
• 1
plas
tic u
nder
shee
t (a
bout
one
sq
uare
met
er)
• 1
unde
rpad
60
cm x
90
cm
• 2
alc
ohol
pad
s
• 2
pac
ks o
f spo
nges
(4
spon
ges)
• 1
ster
ile b
ulb
suck
er
• 2
ste
rile
um
bilic
al c
ord
clam
p
• 1
ster
ile s
urgi
cal b
lade
• 2
cot
ton
thre
ad (
cord
tie
s)
• 1
mat
erni
ty p
ad
• 1
whi
te p
oly
bag
for
disp
osal
• 1
unbl
each
ed d
igni
ty d
rape
• 1
inst
ruct
ion
shee
t
AL
Rad
io c
ontr
ast
med
ia27
0am
idot
rizo
ate
inje
ctio
n14
0mg
to 4
20m
g
iodi
ne/m
l in
20m
l
271
bari
um s
ulfa
teaq
ueou
s su
spen
sion
ESSENTIAL MEDICINES LIST | 91 90 | ESSENTIAL MEDICINES LIST
EML FOR DHQs
DH
Qs
Sr.
#T
hera
peut
ic C
lass
Sr.
#G
ener
ic D
rug
Nam
eFo
rmS
tren
gth
27
2Io
hexo
lin
ject
ion
140m
g to
350
mg
iodi
ne/m
l in
5ml;
10m
l; 20
ml a
mpo
ules
.
AM
Den
tal m
ater
ials
273
NOTES